This brief was developed by the OECD Regulatory Policy Division. It discusses how countries can together manage more effective and consistent responses to the COVID-19 crisis and its vast consequences by learning from each other, ensuring the resilience of supply chains and maintaining the interoperability of essential services through international regulatory co-operation (IRC).

Key messages

The escalation of the COVID-19 crisis into a global pandemic highlights the need for collective action across policy fronts to supplement domestic action and tackle such transboundary challenges in the short and long term, as demonstrated by the many calls from political and international organisation leaders, as well as experts.

However, many countries’ initial policy responses to the pandemic have not been co-ordinated internationally and have exposed the weaknesses in regulatory co-operation. While justified to account for different national realities and various stages of the epidemics, differences in regulatory approaches may also stem from inadequate consideration for the international environment and result in ineffective policy intervention, delays (and even shortages) in access to essential goods and administrative efficiency losses.

Appropriate international regulatory co-operation (IRC) can help manage cross-border risks, promote work-sharing and pooling of resources across government for effective regulatory responses, and reduce costs of production and increased trade of essential goods. It is an important building block of structural regulatory reform to embed resilience in regulatory frameworks.

The current crisis has highlighted a number of areas where IRC can promote sustained and effective regulatory responses and deliver lessons for further collective action:

  • - Exchange of information and dialogue on regulatory matters prove especially useful to adopt emergency regulations when little time is available for research by individual regulator.

  • - Transparency of national regulations, common rules and guidelines on conformity assessment procedures and references to international standards help facilitate availability and trade of essential goods, such as medical products and protective equipment.

  • - Co-operation and regulatory alignment around measures are key to support and maintain the interoperability of essential services such as telecommunications and transportation.

International organisations (IOs) provide a permanent framework for IRC at the international level. They extend the reach of national governments to offer platforms for data and experience sharing; as well as consensus building and the adoption of common approaches. They, however, more rarely have the mandate to support their members in directly managing crisis. Despite its reactivity to continue playing a role as data hub during the crisis, the landscape of international rulemaking is also perceived as complex. Transparency, evidence-based practices and co-ordination across players are all essential to underpin effectiveness and trust.

IRC needs to be firmly embedded in domestic regulatory frameworks. Building bridges with partner countries starts with recognising that international expertise and co-operation can be valuable to achieve national policy objectives. Particularly in times of crisis when rapid action is paramount, tapping on international intelligence and rules can contribute much needed evidence and solutions to feed into domestic rulemaking and delivery. Upcoming OECD Best Practice Principles on International Regulatory Co-operation aim to support policy makers in embedding a stronger international lens in their rulemaking practices.

 Acronyms and abbreviations




American Society for Testing and Materials


Basel Committee on Banking Supervision


Body of European Regulators for Electronic Communications


Bureau International des Poids et Mesures


Collaborative Arrangement for the Prevention and Management of Public Health Events in Civil Aviation


European Committee for Standardization


WCO’s Customs Enforcement Network Communication Platform


European Committee for Electrotechnical Standardization


Coalition for Epidemic Preparedness Innovations


EU Co-ordination group for Mutual recognition and Decentralised procedures


COVID-19 European Medicines Agency pandemic Task Force


European Union Aviation Safety Agency


European Commission


European Medicines Agency


emergency use authorisation, FDA


European Agency for Law Enforcement Cooperation


Food and Agriculture Organization


Food and Drug Administration, United States


Financial Stability Board


Global Initiative on Sharing All Influenza Data


good manufacturing practice


Good Regulatory Practices


Innovative Medicines Initiative, Europe


International Medical Device Regulators Forum


International Air Transport Association


International Accreditation Forum


International Association of Insurance Supervisors


International Civil Aviation Organization


International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use


International Coalition of Medicines Regulatory Authorities


International Electrotechnical Commission


WHO International Health Regulations


Institute of International Finance


International Laboratory Accreditation Cooperation


International Labour Organization


International Maritime Organization


International organisations


International Organization of Securities Commissions


International Organization for Standardization


OECD Mutual Acceptance of Data


Memoranda of Understanding


Mutual Recognition Agreements


Organisation for Economic Cooperation and Development


World Organisation for Animal Health


public health emergency of international concern


personal protective equipment


Regulatory Policy Committee


sanitary and phytosanitary


technical barriers to trade


United Nations Conference on Trade and Development


World Customs Organization


World Economic Forum


World Health Organization


World Trade Organization


The COVID-19 pandemic and ensuing global economic and social crisis are a reminder of interconnected our world has become – and of the importance of co-operation in effectively combating such threats. Thanks to growing interconnectedness, populations worldwide have gained new opportunities and improved their quality of life through travel and trade. Successive technological revolutions allow them to communicate and access information almost anytime, anywhere. While interconnectedness may also have made the world more vulnerable to common threats, it enables us to work together to address them.

In many ways, this crisis illustrates the need for regulatory co-operation in support of domestic action to address the transboundary nature of the challenge. Yet, the crisis also reveals a disconnect between the growing cross-border nature of policy challenges and the traditional national anchor of laws and regulations, the key tools of policy making along with taxation and spending. Acting under pressure and tremendous time constraints, the immediate country reactions have tended to be largely unilateral, seeking national and sub-national solutions and sometimes isolationism to protect from a threat perceived as largely coming from outside. And, indeed, to some extent, the regulatory measures implemented by countries needed to vary depending on the delayed or uneven impacts of the virus, different national conditions and public policy objectives.

Yet, the global health system is as strong as its weakest link. Domestic action to eradicate the virus will only provide short-term success if the virus is not eradicated evenly across country. In addition, the crisis has showed the interdependence of countries in the supply of critical equipment and material, as well as in the delivery of essential products (such as food) and services, with the risk that unco-ordinated action may sever the interoperability of key infrastructure and delay or even break supply chains. Given the complexity and far reaching effects of the policy responses, a key lesson from the early reactions to the crisis is the importance to manage the tension arising from the nationally focused emergency measures taken by countries with the need for international co-ordination to ensure an effective regulatory response.

In the light of the complex dynamics of the regulatory responses to the crisis, this document discusses some of the areas where international regulatory co-operation (IRC) has proved critical to address the COVID-19 crisis and the mechanisms that governments can rely on to articulate a co-ordinated and consistent regulatory response while preserving their national prerogatives to adapt the approach to their specific circumstances. Given the speed of the responses that the crisis requires, IRC needs to be strongly embedded ex ante in regulatory frameworks to be mobilised on time – this is for example the case of the variety of international organisations and networks of regulators that provide institutional platforms for on-going exchange of information and joint regulatory approaches. The institutionalisation of IRC is a key dimensions of resilient regulatory frameworks.

To review the evidence on the IRC responses to the crisis and its organisation, the paper is structured around three sections: i) the first section describes the current calls for IRC and its rationale; ii) the second section discusses the areas that have emerged through the current crisis where IRC is most needed to support effective policy responses; and iii) the third section reviews how IRC is organised, through the activities of international organisations, and the national conditions required for effective IRC.

The paper builds on the extensive work on IRC developed by the OECD Regulatory Policy Committee (RPC) over the past 9 years. It is part of a series of responses to the COVID-19 crisis developed by the OECD Regulatory Policy Division, starting with a framing piece on Regulatory Quality and Covid-19: Managing the Risks and Supporting the Recovery1 and encompassing five other contributions.2 This work is published under the responsibility of the Secretary-General of the OECD. The opinions expressed and arguments employed herein do not necessarily reflect the official views of OECD member countries. It was prepared by the Secretariat and submitted for comments to the RPC, the Network of Economic Regulators and the Partnership of International Organisations for Effective International Rulemaking. It will be edited and improved over time as more information becomes available.

 Rationale for IRC: Collective action to fight common threats

 COVID-19 and its consequences highlight the need for international co-operation and a co-ordinated approach

The COVID-19 crisis has highlighted the many consequences that globalisation has on our daily lives. The rapid spread of the virus across the world in the course of 3 months,3 has highlighted more than any other event the huge interdependencies of our world economy, and the risks that come with it. While billions of citizens worldwide are in a lockdown, unable to leave their homes and let alone travel, globalisation that has been taken for granted by so many until now is suddenly facing a “short circuit” (Gomart, 2020[1]).

While necessary, domestic solutions will be insufficient on their own to address the global health crisis. All countries are affected by the same reality: needing to face a public health crisis and drastic containment and mitigation measures, with immense consequences on employment, income, wellbeing and more broadly on economic growth (OECD, 2020[2]) (OECD, 2020[3]). Both short and long-term responses urgently require global co-ordinated action, whether to contain the epidemic, develop a vaccine or ensure appropriate healthcare to populations throughout the world. Infectious diseases know no borders, and neither should government responses to face them. Most importantly, even if a country manages to completely contain or even eradicate the disease on its territory, these efforts risk failing if not followed by other countries:

(…) if we do nothing as the disease spreads in poorer African, Asian, and Latin American cities and in fragile communities which have little testing equipment, ventilators, and medical supplies, and where social distancing and even washing hands are difficult to achieve, COVID-19 will persist there and re-emerge to hit the rest of the world with further rounds that will prolong the crisis. (Berglöf, Brown and Farrar, 2020[4])4 

Looking towards the longer-term, once lockdown measures start to be eased, economic recovery will depend on the effectiveness of the policy actions taken to support workers and companies in a post-COVID world (OECD, 2020[3]).

A number of heads of government, political leaders, international organisations and experts have made strong calls for international co-operation to develop policy responses that address both the short and long term challenges raised by this crisis. Some focus on the need of financial co-operation to increase funding towards international institutions, whether to allow for these institutions to better deliver on their mandate, to increase the global production and procurement of medical supplies, to contribute to the rapid development of a vaccine, or to support countries with weaker health systems and especially vulnerable populations, among others (Berglöf, Brown and Farrar, 2020[4]). In late March 2020, G20 Leaders issued an emergency statement on COVID-19, highlighting the intrinsically international nature of the causes of the current crisis and therefore the importance of international solutions to it:

The unprecedented COVID-19 pandemic is a powerful reminder of our interconnectedness and vulnerabilities. The virus respects no borders. Combating this pandemic calls for a transparent, robust, coordinated, large-scale and science-based global response in the spirit of solidarity. We are strongly committed to presenting a united front against this common threat. (G20, 2020[5])

The United Nations General Assembly adopted a resolution on 2 April 2020 on “Global solidarity to fight the coronavirus disease 2019 (COVID-19)”, reaffirming its commitment to international co-operation and multilateralism:

[The General Assembly] Calls for intensified international cooperation to contain, mitigate and defeat the pandemic, including by exchanging information, scientific knowledge and best practices and by applying the relevant guidelines recommended by the World Health Organization (United Nations General Assembly, 2020[6])

Similarly, Foreign Ministers from 54 jurisdictions issued a joint declaration in favour of global co-operation and solidarity to fight COVID-19:

Containing and countering this pandemic calls for a co-operative, transparent, science-based and coordinated global response. (Alliance for Multilateralism, 2020[7])

Calls for an international response have also centred on co-ordination of regulatory and policy actions to tackle the immediate public health emergency, buffer the economic shock and develop a path towards recovery. As highlighted by the OECD Secretary-General:

Today, regulatory agencies (the FDA in the US, the European EMA, among others) should work together to remove regulatory hurdles for vaccines and treatments (…);

Governments should advance joint policies, rather than taking them in an unco-ordinated way. (…)

Central Banks have already launched bold actions to support the economy but financial regulation and supervision is another area where co-ordination could produce better outcomes. (…)5

International co-operation can also help prevent unintended consequences of hasty national regulations. In particular, heads of the UN Food and Agriculture Organization (FAO), the World Health Organization (WHO) and the World Trade Organisation (WTO) called on governments to remain cautious when adopting national measures that these do not disrupt the food chain and lead to food shortages, particularly risky for most vulnerable and food insecure populations:

It is at times like this that more, not less, international cooperation becomes vital. In the midst of the COVID-19 lockdowns, every effort must be made to ensure that trade flows as freely as possible, specially to avoid food shortage. (…). We must also ensure that information on food-related trade measures, levels of food production, consumption and stocks, as well as on food prices, is available to all in real time. (…) (FAO, WHO and WTO, 2020[8])

 What can we expect from international regulatory co-operation?

The calls for action in times of COVID-19 insist on the importance of international co-operation, in particular in the regulatory field. Indeed, solving the health and ensuing economic and social crisis involves regulatory issues at nearly every stage and in most areas. Regulation6 affects the availability of tools and products to identify and fight the disease in all countries (tests, products and devices). Regulation frames the ability of public utilities to maintain critical services, of food and other vital products to be produced and delivered, of essential services to continue functioning – even in a lockdown situation where much of the economy and of both private and public sectors stop functioning normally.

In a globalised context, regulations adopted will have significant effects for all those within a same country, but also well beyond its borders: to be able to trade products, import inputs and contribute to global value chains, companies have to adapt to the regulations of a wide range of countries of origin and destination. Particularly when production chains are fragmented across various countries, as many regulations as there are jurisdictions can apply to one same product (OECD, 2017[9]). Adapting to multiple regulatory requirements can be especially challenging in times of crisis and slow down access to essential foodstuff, medical products and devices among others. One can hardly imagine any situation in which the need for trusted, evidence-based, internationally co-ordinated and well enforced regulation is more obvious than now (OECD, 2020[10]).

International regulatory co-operation is fundamental to ensure countries achieve an adequate regulatory response to this global crisis, and ensure resilience of their regulations for the longer term. Regulations are adopted by each country following their national processes. However, given the global nature of the current crisis, the potential impact of the regulations designed to address it will have a global reach. OECD research over the past decade highlights a variety of benefits from IRC and its contribution to countries in achieving their policy objectives in a globalised context (OECD, 2013[11]), many of which are instrumental in the context of the current crisis.

First, IRC is essential to manage cross-border risks and externalities that regulators will not be able to address from a purely domestic angle. The spread of the virus throughout the world and its escalation from an epidemic to a pandemic7 presents inherently transboundary risks that cannot be prevented by national regulators alone. Indeed, the constant travel, trade and connectivity which characterise our world today are the first factor in causing an increase in global disease outbreaks (WEF, 2019[12]). Regulations designed without considering the impacts beyond their jurisdiction are suboptimal, potentially ineffective if they overlook transboundary regulatory benefits and overly burdensome if they disregard transboundary regulatory costs (OECD, 2013[11]; Esty and Geradin, 2000[13]). In this sense, unless they account for their transboundary impact, regulations aiming to address the pandemic risk being too weak to achieve their primary public health objectives of containing and mitigating the disease, and generating excessive costs, including for businesses in other jurisdictions. More broadly, in the context of COVID-19, a co-ordinated, multisector approach among relevant national and international actors is essential to address the multifaceted challenges that a zoonotic virus (that spreads between animals and people) has to human, animal and environmental health as a whole. This approach is particularly highlighted by the “One-health” concept developed by the FAO, the World Organization for Animal Health (OIE) and the WHO.8

Second, IRC enables work-sharing across governments and public authorities, thus reducing the “learning curve” when facing new policy challenges. As such, the peer learning gained through IRC allows governments to develop regulatory action faster and more effectively, resulting in administrative efficiencies. This is clearly demonstrated for example in the chemicals sector, where the OECD Mutual Acceptance of Data (MAD) system helps governments and industry save more than €309 million per year through reduced chemical testing and the harmonisation of chemical safety tools and policies across jurisdictions (OECD, 2019[14]). The co-operation has brought health and environmental gains from governments being able to evaluate and manage more chemicals than they would if worked independently. The pooling of know-how has helped develop new and more effective methods for assessing chemicals. In this way, not only are government resources saved, but products can also be brought to market faster (OECD, 2013[15]) (OECD, 2019[14]). Similar co-operation can be of great relevance in the health field as countries face a new virus of unprecedented form and scale. Through IRC, regulators can learn from the measures adopted in jurisdictions that were first to experience COVID-19 outbreaks and quickly disseminate best practices.

Finally, IRC can generate economic efficiency gains through reduced costs of production and increase trade and investment flows (OECD, 2013[11]) (OECD, 2017[9]). Governments are responding to the crisis with numerous regulatory measures, some of which may have significant impacts on trade and investment. Regulatory differences among the jurisdictions involved in supply chains generate a number of costs for traders, including of gathering information on various regulatory requirements, of adapting specification of goods and services to comply with these different regulatory requirements and of undertaking various conformity assessment procedures to demonstrate compliance (OECD, 2017[9]). IRC can help governments limit the unnecessary costs through the design of measures that are as coherent as possible with those of their trading partners. This starts with disclosure of and exchange of information about draft measures, to enable collaboration in the very early stages of developing new measures. In the context of COVID-19, the WTO has underscored the importance to “…pool information within a multilateral platform to avoid duplication of efforts and to increase efficient collaboration”, and set up a dedicated website and guidance tools to support its Members in this direction (WTO, 2020[16]). The WTO has also established a dedicated space on its website where all COVID-related notifications - submitted under various WTO Agreements can be found.9

 Initial countries’ policy responses to the pandemic have often not been co-ordinated internationally

Despite the strong calls for co-operation, for the most part the immediate regulatory reactions to COVID-19 have been unilateral (Grimalda, 2020[17]), including at the European level (Russack and Blockmans, 2020[18]) where strong co-operation mechanisms are in place. Many countries have sought national solutions and sometimes isolationism to protect from a threat perceived as largely coming from outside. This partly owes to the fact that countries’ regulatory practices are still very much built around mostly domestic processes, using national evidence and considering impacts at the national level (OECD, 2018[19]) (OECD, 2018[20]) (OECD, 2020[21]). There is also an element of a Prisoner’s dilemma in the current situation (OECD, 2013[11]) where countries seem to have given priority to the short-term emergency solutions that come with unilateral actions (maybe to assuage what they perceive as the concerns of their citizens) instead of choosing more co-operative solutions.

Countries have often resorted to international travel restrictions, known to delay but not prevent pandemics (OECD, 2020[22]). Though the effects of these travel restrictions are still to be seen, initial studies suggest that the unco-ordinated closure of borders in the European Union has been particularly harmful for certain countries who rely strongly on the free movement of labour and goods across Europe, such as the Baltic States, Bulgaria and Romania reliant on remittances of their nationals working in other EU countries. In the same vein, even non-EU Members within the Schengen zone have suffered from unilateral restrictions on EU external borders (Russack and Blockmans, 2020[18]).

Some unilateral approaches have had an especially visible and harmful effect on trade (OECD, 2020[23]). With regards to medical supplies alone, 24 nations have taken steps to ban or limit the export of medical equipment such as masks, medicines, and their ingredients, while certain national measures also restrict imports of medical equipment, thus limiting access to such goods for their own population (Evenett, 2020[24]). Measures such as requisitions, advanced shipment notifications, stockpiling requirements, confiscations, or export restrictions on specific products only adopted unilaterally by certain countries have created significant costs for businesses, seriously affecting the trade in medical and protective equipment and medicines - from raw materials to finished pharmaceutical forms. In April 2020, representatives of the health industry expressed their concern about such measures, and alerted the EU Trade Ministers of the harms that such measures could have, in particular to:

amplify or increase the risk of supply shortages, disrupt distribution channels, hinder the conduct of clinical trials, lead to imbalances between supply and demand, and risk retaliatory measures from trading partners that could likewise impact patients in other countries. 10

The effectiveness of the different policies implemented by countries to contain and mitigate the virus at varying degrees of strength can only be assessed in the longer run. However, most countries have lagged behind in their responses and mostly missed the opportunity to prepare and learn from other countries’ experience although information about the outbreak was available globally from its early stages.11 Yet domestic solutions are insufficient to address a transnational health problem. Against this background the following sections highlight the areas where international regulatory co-operation has or could help achieve a better and more effective response to address the pandemic and protect the health and safety of people, maintain trade in essential products and foodstuff, and prepare for economic and social recovery.

 IRC in support of the responses to the COVID-19 crisis

As governments react rapidly and across a wide range of policy areas to face the COVID-19 crisis, domestic regulatory action is at the centre of the response. Still, on a number of areas, IRC is key to secure effective and sustainable response to the global health threat. A variety of approaches are available to countries to co-ordinate on regulatory matters and policies. The OECD has identified a typology of approaches that ranges from unilateral efforts to embed international considerations in evidence-based rule-making, to co-operative approaches – bilaterally, regionally or multilaterally –, including exchange of information on measures, mutual recognition efforts and joint development of international rules through international organisations (OECD, 2013[11]). The Statement from G20 Leaders highlights a range of these as priorities:

We will share timely and transparent information; exchange epidemiological and clinical data; share materials necessary for research and development; and strengthen health systems globally, including through supporting the full implementation of the WHO International Health Regulations (IHR 2005).(…) We task our Health Ministers to meet as needed to share national best practices and develop a set of G20 urgent actions on jointly combatting the pandemic by their ministerial meeting in April. (G20, 2020[5])

The COVID-19 crisis has already made apparent specific areas where IRC is critically needed to achieve successful regulatory outcomes across policy sectors. In line with the general benefits of IRC discussed in the previous section, these areas include:

  • Areas where IRC can promote work sharing, mutual learning and pooling of resources between governments in adapting their regulatory policy to face the crisis;

  • Areas where IRC can support the resilience of supply chains and enable the availability of essentials, such as medical and food supplies and medical countermeasures to fight COVID-19; and

  • Areas where IRC can facilitate the interoperability of services and cross-border activities.

This section discusses how international regulatory co-operation supports policy interventions in response to the COVID-19 crisis and the IRC mechanisms used for these purposes. The specific areas discussed below do not intend to be exhaustive but to present an illustration of concrete challenges which IRC can help address. Additional challenges with a strong rationale for international regulatory co-operation will surely emerge in the medium and long-term response to the crisis, as well as to pave the way for recovery. This section will be updated progressively as the evidence is gathered.

 IRC promotes work sharing, mutual learning and pooling of resources between governments

Dialogue between regulators and exchange of information is the bedrock of IRC. Facing the COVID-19 crisis, countries have promoted and accelerated exchange of data and information on different fronts. Typically, regulators can agree with their peers (bilaterally or internationally) by gathering in conferences, fora, or other settings to exchange information and experiences on regulatory issues, and help each other in the development of measures at home (OECD, 2013[11]).

Exchange of scientific information and a common understanding of the virus is critical in supporting regulatory co-operation in key areas. The spread of COVID-19 has triggered unprecedented scientific collaboration among a host of state and non-state actors, including experts and researchers from different scientific communities, regulators, and policy-makers. These actors organise around platforms and networks, some of which hosted or promoted by government together with international organisations. Several of these arrangements are supported by the World Health Organisation (WHO), the leading intergovernmental organisation in the field of health (OECD/WHO, 2016[25]). Many exchanges also take place in other organisations (see last section of this paper), and co-ordination between IOs in this regard can help further foster scientific progress. For example, WHO works jointly with the World Organisation for Animal Health (OIE), the Food and Agriculture Organization of the United Nations (FAO) to identify the zoonotic source of the virus and the route of introduction to the human population (WHO, 2020[26]). Box 1 provides examples of non-state actor’s involvement in the COVID-19 response and Section 3 provides a more detailed description of initiatives by international organisations.

Exchange of scientific information can anticipate and build the ground for subsequent regulatory co-operation to enable the development and wide availability of COVID-19 diagnostic kits, therapeutics and vaccines (OECD, 2020[27]) (Patel and Salisbury, 2020[28]). The review and approval of diagnostic kits, treatments and vaccines take place at a national level. Despite the premises of a common international framework for pharmaceutical and medical device regulations as provided by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)12 and the International Medical Device Forum (IMDRF),13 the system is far from a united regulatory framework as highlighted by a number of observers14. Unco-ordinated regulatory approaches across countries slow down and hamper the development and availability of drug products due to fragmented, contradictory and/or duplicative requirements. Scientific efforts to develop treatments, tests and vaccines should be paralleled with co-operation across regulators to ensure that these products are widely available – particularly for vaccines as the consequences of partial coverage would have a global reach. Co-ordination can include agreements to use standardised protocols, fast-track procedures to clear treatments, tests and vaccines; and expedite regulatory approval pathways for new diagnostic and immunity tests. The EU Guidelines on COVID-19 in vitro diagnostic tests are a good example of this approach (European Commission, 2020[29]).

Action on this front is already taking place, a group of global health actors15 launched the Access to COVID-19 Tools (ACT) Accelerator, a global collaboration to speed-up and harmonise processes to ensure the development, production and equitable access to new diagnostics, therapeutics and vaccines for the virus (WHO, 2020[30]). Similarly, the European Medicines Agency (EMA) has established a COVID-19 EMA pandemic Task Force (COVID-ETF) to promote quick and co-ordinated regulatory action on relevant medicinal products, including on protocols and development plans for COVID-19 medicinal products, including vaccines and therapeutics (EMA, 2020[31]). Regulatory co-operation to make a new vaccine available can also involve further transparency and sharing of information on intellectual property rights in order to foster innovation and enable equal access to the vaccine (Stiglitz, Jayadev and Prabhala, 2020[32]).

Scientific consensus is also needed to forge trust across countries around the design of effective intervention packages to control the epidemic and phase-out social-distancing and/or lockdown measures. For example, the Joint European Roadmap towards lifting COVID-19 containment measures recognises that co-ordinated action between the Member States should be based on science and includes actions to gather harmonised data and align testing methodologies to better manage the lifting of measures (European Commission, 2020[33]). Reaching this consensus and using scientific evidence to develop measures requires countries to trust each other’s data and information, and more broadly their regulatory frameworks and institutional capacities. International co-ordination and standardisation of methods can support the comparability of serological testing results, an important pre condition to monitor the virus transmission and help design targeted remedial policies (Bryant et al., 2020[34]).

When regulators pool together their experience and expertise, they reduce the risk of regulatory failure and promote good regulation. As countries face outbreaks weeks or months apart, there is a window of opportunity for governments to disseminate and exchange information on their containment and mitigation measures to curb the spread of the virus. Shared information can include analysis of the effectiveness of containment and mitigation measures, the main challenges faced around their implementation and enforcement, compliance data, and communications strategies, to name a few. Once the virus transmission is brought under control and countries gradually resume activities, exchange of information on strategies and experiences on how to relax containment measures and regulate the re-opening of business and activities can help understand and disseminate successful and less successful practices and lessons learned to countries that follow in the restart of their activities or in potential second-wave outbreaks of COVID-19.

Sharing of experiences can prove especially useful to adopt and review emergency regulations. Many governments have passed special regulations in reaction to the crisis following normal rulemaking processes or through fast-track procedures enabled by emergency laws. A number of these regulatory efforts lift, adjust or simplify existing rules and technical regulations dealing with medical products and disinfectants.16 Some of these measures are temporary in nature and include sunset clauses or review windows to ensure that they remain in effect only for the duration of the emergency. For instance, half of the COVID-19 related TBT and SPS measures notified to the WTO are reported as temporary (WTO, 2020[35]). The sharing of experience on the temporality of these emergency measures can in itself be a helpful step for other governments putting in place temporary emergency measures. In addition, once the early stage of the crisis is over, or its impacts are below a critical threshold, carrying out ex-post reviews and sharing their results across jurisdictions could usefully inform national policy makers and the international community of the effectiveness of these emergency measures for future crisis. Dissemination can be facilitated by centralising information on COVID-19 related measures. Some of these have been notified to the WTO in line with the transparency provisions of the TBT and SPS Agreements (WTO, 2020[35]). In addition, several governments and regulators list all their COVID-19 related measures in online platforms, enabling easy access to other regulators to learn from these (Box 2).

Pooling of expertise and intelligence sharing can also help countries as they adapt their usual regulatory activities to unprecedented conditions. Governments have reorganised rulemaking and regulatory delivery across policy areas. They have modified compliance requirements to allow business adjust and/or prioritise crisis-related activities; adapted a number of administrative procedures as well as inspections activities to account for new health and safety measures; and rolled out communication strategies to guide consumers and industry in understanding and complying with regulation in a crisis situation. Regulators responsible for essential services such as telecommunications, energy, water and transport, have rapidly implemented measures to adapt their operations to secure provision of services, protect customers and bolster the efficient use of resources and competition. The importance of co-ordinated action and information sharing has been highlighted, as a variety of public bodies are required to act jointly to uphold the functioning of markets. Exchange of information on these measures is key and is already taking place, mainly through existing sectoral or regional networks of regulators – this is the case, for example, of current discussions in the OECD Network of Economic Regulators highlighting the adaptation of their regulatory processes to these exceptional times in order to uphold the delivery of key public services (OECD, 2020[10]).

Regulatory co-operation can help consolidate resources and co-ordinate regulatory delivery across borders. The health emergency challenges the normal vigilance of compliance with regulations, typically based on paperwork and physical inspections or controls of goods or facilities. Regulators may collaborate across jurisdictions through common enforcement and inspection strategies as they adapt administrative requirements to ensure additional health and safety measures for public officials. For example, the EU exceptionally authorised official controls related to food and feed law, animal health and welfare, and plant health and plant protection, to be performed by any person specifically authorised by the competent authority and conducted by electronic copy of the original of official certificates or attestations, instead of the physical original documents usually required (European Commission, 2020[36]). Co-ordination of regulatory delivery can further extend to sharing on inspections plans, and ultimately co-ordination of inspection procedures, in order to avoid unnecessary duplications and save time for companies. The EU, EMA and the national competent health authorities agrefed on measures to mitigate the impact of disruptions on inspections of manufacturing facilities or other sites relevant for medicinal products for human use. The measures include, for instance, granting certain authorisations without a pre-approval inspection (EU, 2020[37]).

Regulators can act together to face new enforcement challenges created by the COVID-19 outbreak. Markets have seen a surge of fraudulent products that claim to prevent, treat, mitigate, diagnose or cure COVID-19. To protect consumers and patients, regulators have taken measures to monitor and halt these products. By 14 May 2020, the United States Food and Drug Administrator (FDA) had issued 49 warning letters to firms for commercialising such products.17 On 6 April, the European Agency for Law Enforcement Cooperation (EUROPOL) supported an investigation that resulted in the arrest of criminals purporting to sell masks to EU Member States’ governments and helped foil another attempt to swindle millions of Euros out of authorities for medical supplies.18 For instance, exchange of information through joint rapid alert systems and a common approach to the monitoring of these products and their recall, could facilitate the response by regulators. International organisations play an important role in orchestrating the exchange of information – see Section 3 for a description of their role.

Box 1. The complementary role of State and non-State actors in the COVID-19 response

Since the outbreak of COVID-19, there has been a strong acceleration of efforts involving a variety of state and non-state actors to advance the development of vaccines and treatments. Scientists and pharmaceutical industry representatives from around the world are working together, regardless of their country of origin. Researchers, health, technology and pharmaceutical companies have come together through special platforms, many of which build on existing networks such as CEPI (Coalition for Epidemic Preparedness Innovations), Europe’s IMI (Innovative Medicines Initiative), the Global Initiative on Sharing All Influenza Data (GISAID), and the Bill and Melinda Gates Foundation (OECD, 2020[22]).

Action to fund R&D efforts and to secure country’s preparedness to face the pandemic have also brought together state and non-state actors. Joining the call for action by global health partners, the European Commission launched on 4 May 2020 a Coronavirus Global Response pledging event.19 The aim is to gather significant funding to ensure the collaborative development and universal deployment of diagnostics, treatments and vaccines against coronavirus. As of early June, it had registered some €9.8 billion, equivalent to $10 billion, in pledges from donors worldwide. The Global Vaccines Summit that Gavi, the Vaccine Alliance, organised on 4 June 2020, aims to mobilise additional funding to protect the next generation with vaccines. Such financial support for a global pandemic response serves as a corollary to country’s common regulatory action regarding the vaccine.

Box 2. Repositories of regulations related to COVID-19

Several governments have consolidated their COVID-19 related regulations in online platforms, enabling easy access to the public and allowing other regulators to learn from these.

Canada centralises the information on legislation, charter statements, orders and regulations adopted in response to COVID-19, including details on dates of effectives on the Department of Justice website: www.justice.gc.ca/eng/csj-sjc/covid.html. Japan includes on its Government website the basic policies for the prevention and control of COVID-19 https://japan.kantei.go.jp/ongoingtopics/_00013.html.

Mexico’s National Commission for Regulatory Improvement (CONAMER) centralises the information on regulatory responses to COVID-19 at a federal, state and municipal level: https://conamer.gob.mx/respuestas-regulatorias-covid-19/.

South Africa has made available all regulations and guidelines on COVID-19 in a single location on the government website: www.gov.za/coronavirus/guideline.

The EU’s coronavirus response website provides an overview of national measures adopted in the area of transport, border/free movement restrictions and in support of the economy: https://global-response.europa.eu/index_en.

Sectoral regulators have also made available lists of emergency authorisations or regulations.

In the United States, the FDA lists all current and terminated Emergency Use Authorisations (EUAs) diagnose and respond to public health emergencies: www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#coronavirus2019. The website includes COVID-19 EUAs that make available PPE, medical devices, in vitro diagnostics, and SARS-CoV-2 antibody tests, among others.

 IRC supports availability of essential goods

One of the immediate issues arising from the COVID-19 crisis has been ensuring populations worldwide access to essential goods despite travel restrictions and highly affected production capacity. These include food items and disinfectant as well as critical medical equipment and medicines needed to fight the virus, or “COVID-19 products”. Many of these goods are produced across a number of countries. Depending on their complexity, they may be the result of long value chains building on inputs and assembled in different countries; or they may also be components of a broader package of products from different countries, as illustrated by diagnostic tests, which require complementary equipment such as swabs and reactive. As a result, their availability relies heavily on trade as no single country efficiently produces all goods it needs (OECD, 2020[23]). Given the current reality of fragmentation of production throughout the globe, the free flow of trade in goods is crucial to ensure the supply of essential products and to send a signal of confidence for the global economy (OECD, 2020[38]).

To prevent shortages on medical or other essential products, some countries have imposed temporary export restrictions or prohibitions, a strong form of regulatory action, at the risk of cutting-off countries reliant on imports from accessing these goods and triggering a supply shock (WTO, 2020[39]). As of late April 2020, some 80 countries and separate customs territories had introduced export prohibitions or restrictions as a result of the COVID-19 pandemic (WTO, 2020[39]). In the short run, such restrictions and prohibitions may help increase domestic availability and reduce domestic prices, and therefore prove useful to fight the virus at the national level. However, albeit temporary, these export restrictions and requisitioning of domestic production of essential medical supplies may have unintended consequences at the international level, reducing access to critical supplies, increasing average prices, augmenting market volatility, and distort investment decisions, with adverse effects both in the short and in the long run (Fiorini, Hoekman and Yildirim, 2020[40]). The effects of numerous export restrictions will have particularly negative consequences for developing countries who lack domestic manufacturing facilities that their governments could instruct to suddenly scale up production (Bown, 2020[41]). Transparency and international co-operation is therefore essential among countries to strike a balance between the shortages in essential medical products in some exporting countries and the negative impact that such measures may have on public health of other importing countries (WTO, 2020[39]). Transparency and co-ordination on policy approaches can allow to maintain international trade in essential goods from countries where they are abundant, to those where they are lacking, all the more that the disease peaks at different times in different locations (WTO, 2020[39])

Without going to the extreme of export restrictions, unnecessary burdensome or divergent “behind the border” regulations may significantly slow down, limit or completely halt international trade of essential goods. Indeed, in most countries essential COVID-19 products tend to be heavily regulated and subject to strict certification and licence requirements to guarantee their quality. The accumulation of divergent regulatory requirements across jurisdictions may create important frictions and even barriers to their trade across countries.

IRC can enable the availability of key COVID-19 supplies by limiting export restrictions and unnecessary regulatory frictions. Co-ordinated policy responses between countries can limit incentives for export restrictions (Pauwelyn, 2020[42]). For example, the European Commission took a number of steps, including a regulation20 and related guidance21 establishing export authorisations by Member States for protective equipment outside of the European Union,22 de facto abolishing these measures among EU Members. As a result, nearly all Member States lifted their national export restrictions and the protective equipment could be delivered seamlessly across the Union to where it was most needed. Regarding the potential of IRC to help address trade frictions arising from divergent regulations, discussions in the WTO’s Technical Barriers to Trade Committee (TBT Committee) draw light on the regulatory divergence issues typically affecting trade in medical goods and a number of IRC solutions:

Can products which can prove conformity with international standards be allowed entry without additional checks? Can duplicative testing be reduced – for instance, can trading partners accept tests from other countries instead of requiring re-testing in their own labs? Can inspection frequency be reduced based on risk assessment, so that only the highest risk shipments receive greater scrutiny? Can an audit of a manufacturing facility (of the most risky and sensitive products) by your trading partner be relied upon by your own authorities, rather than conducting an additional repetitive audit? (Lim, Locks and McDaniels, 2020[43])

Governments can take a number of measures to address these challenges and ensure availability of COVID-19 products, improving trade facilitation through priority lanes, adopting international standards, among others (González, 2020[44]). These include typically transparency measures, agreements on common approaches, adoption of international standards and recognition approaches. Transparency and exchange of information on draft measures allow countries to work towards coherent action to prevent regulatory divergences from becoming unnecessarily significant. Alignment of national approaches around international standards allows to scale up production and facilitate public procurement. Unilateral or mutual recognition of test or inspection results or co-operation on enforcement can help speed up procedures and prevent excessive burdens at the border when countries have differing regulations in place – this implies some alignment in risk appraisal across jurisdictions. These measures are further elaborated in the sub-sections below.

Transparency to maintain trade flows of essential goods in times of COVID-19

Real-time information about what products are needed and how they are commercialised in different countries can avoid disruptions to international trade in times of crisis. Governments have made numerous pledges in favour of transparency of market supplies and regulations to maintain trade flows in food and medicinal products in particular,23 followed up with different co-operative initiatives to share such information and guarantee transparency to keep up the trade flows of essential goods described in following paragraphs.

Transparency of supplies of goods available on the market helps to ensure that Government policy responses are well adapted to the actual, rather than perceived demand and supply disruptions in times of crisis (FAO, 2020[45]). With this in mind, the Agricultural Market Information System24 was launched in 2011 in response to the food price crisis of 2007/08, and has contributed to maintain stability in global food markets and promoted policy co-ordination. In the Covid-19 crisis, this information system has shown its value to guarantee global food security and nutrition, because the food system as a whole is impacted (as opposed to only certain products in other crisis) (Fernandes Guimarães and Haniotis, 2020[46]). The G20 countries therefore committed to “continue providing timely and reliable information on global food market fundamentals to help markets, countries, and consumers make informed choices” and co-ordinate policy responses on this basis (G20, 2020[47]). Similar mechanisms could also be envisaged for non-food products needed to respond to public health emergencies (Hoekman, Fiorini and Yildirim, 2020[48]). For example, the WHO and the World Economic Forum (WEF) set up the Pandemic Supply Chain Network, a public-private organisation to facilitate the functioning of this supply chain for personal protective equipment. This new mechanism aims to provide market visibility, technical guidance and country and global demand scenarios to governments, UN partners and private sector organisations (WHO, 2020[49]).

Transparency of domestic regulations – whether trade restrictive, trade facilitating, or simply having some form of impact on trade – helps to strengthen legal predictability and certainty. In particular, the notification of draft or adopted measures to the WTO opens the possibility for dialogue between countries to work towards coherent regulations and prevent trade disruptions through regulatory co-operation (OECD/WTO, 2019[50]) (Karttunen, 2020[51]). Such transparency allows for “…governments and traders to keep up to date in a rapidly evolving trade landscape and provides much-needed clarity” (WTO, 2020[16]). This is especially important in times of crisis (Lim, Locks and McDaniels, 2020[43]; WTO, 2020[16]), and G20 countries pledged to notify all trade related emergency measures designed to tackle COVID-19.25 The notifications of measures relevant to COVID-19 have been compiled by the WTO Secretariat within a single web portal.26 Around two-thirds of these notifications are related to TBT and SPS (WTO, 2020[35]). Relying on “ePing”, the electronic alert system related to SPS and TBT measures notified to the WTO, stakeholders can receive real time information on new COVID-19 measures specifically.27 Even in cases where measures are directly adopted and notified under the emergency provisions of the SPS and TBT Agreements, without the usual comment period, they allow for private actors to gain predictability about new procedures and regulations that may apply to the imports or exports of their products (WTO, 2020[35]). To date, 42 out of 156 WTO members have notified the WTO with a total of 134 notifications related to COVID-19.28 A closer look at the current transparency practices about COVID-19 measures suggests that these remain limited, highlighting a potential that could further be utilised (Wolfe, 2020[52]).

The World Customs Organisation (WCO) has also created repositories of temporary import29 and export30 measures on certain categories of critical medical supplies that complements the information on these measures available through the WTO; and, together with the Commonwealth Small States Office, the Global Alliance for Trade Facilitation, the International Air Transport Association (IATA), the International Trade Centre, the United Nations Conference on Trade and Development (UNCTAD), and the WTO, it has set up a repository of trade facilitation initiatives adopted across the world.31

Beyond notification, the European Commission has also developed a number of increased transparency guidelines specific to transport-related measures under its general efforts to set up “Green Lanes” (See below).32 The guidelines recommend that any restrictions to the transportation of goods and passengers imposed as part of COVID-19 response remain transparent, duly motivated, proportionate, relevant and non-discriminatory. In this line, the Commission requires transport-related restrictions be notified by Member States and has set up an internal electronic platform for EU members to inform all national transport measures adopted in response to the coronavirus.

Development of common approaches, such as agreements on simplified procedures and adoption of international standards to facilitate flow of essential goods

Acknowledging the high risks of slow and burdensome border controls, particularly of food and medical goods, different co-operation measures can be adopted both to facilitate transit at borders, and to reduce potentially costly and time consuming conformity assessment procedures and market surveillance (OECD, 2020[53]). In addition, IRC can help guarantee that products traded across the globe meet comparable levels of safety and health protection.

A common understanding of the specific products that are relevant to fight COVID-19 can go a long way to focus regulatory co-operation across countries and in fine facilitate their availability. Generally, national authorities define the essential COVID-19 goods that should be target of priority regulatory and custom measures to facilitate their availability. While there is no common international definition of these products yet, the WCO has developed guidance on how to establish and use essential goods lists during a disaster (WCO, 2020[54]). Other international organisations, including the World Bank Group and the WTO, are developing complementary lists (OECD, 2020[23]). To help countries speed up the cross-border movement of COVID-19 medical supplies, the WCO and WHO have developed a harmonised system classification list for these products and a list of priority medicines for custom clearing (WCO/WHO, 2020[55]) (WCO/WHO, 2020[56]).

Countries have agreed on simplified customs procedures and established “Green lanes” to accelerate and secure cross-border trade of goods (González, 2020[44]). This was initially done in China to facilitate internal trade between customs districts during the outbreak.33 Similarly, the European Union developed guidelines introducing simplified border procedures for drivers of freight vehicles and the acceptance of electronic documents by border officials to guarantee the flow of goods in the internal market.34 They also provide additional measures at external EU borders to ensure appropriate health care. Additional entry and exit screening measures are recommended as well as isolation of suspected cases and the provision of information material. The EU plan for lifting containment measures includes the creation of a rapid alert function to identify supply and value chain disruptions, relying, inter alia, on existing business and trade networks as well as social partners (European Commission, 2020[33]).

International standards are a central piece of regulatory alignment as they enable the harmonisation of technical specifications of products (OECD, 2013[11]). They play a key role in sectors where trade is important, including medical products, to reduce frictions related to undue regulatory divergences and contribute to the transfer of technology from developed to developing countries.35 International standards can promote availability of products by helping ramp up production and facilitating public procurement. More broadly, international standards can help build trust in novel technologies so that they can be quickly and efficiently deployed to help combat COVID-19 (Madzou, 2020[57]). Against this background, the WTO SPS and TBT Agreements strongly encourage WTO members to use relevant international standards, guidelines and recommendations as the basis for their measures (OECD/WTO, 2019[50]). In the context of COVID-19, using international standards as a basis for domestic measures may prove particularly useful to ensure they are de facto coherent with those chosen by other countries.

The EU provides an example of the use of joint standards for regulatory purposes in support of the responses to COVID-19.36 The EU Commission, the European Committee for Standardization (CEN) and the European Committee for Electrotechnical Standardization (CENELEC), have made freely available 11 pre-existent European standards for medical devices and personal protective equipment, including masks, gloves, and other PPE (European Commission, 2020[58]). This aims to help companies in the EU and other countries to start production and place products in markets while ensuring a high degree of safety. Regulatory alignment around international standards has also enabled EU countries to launch joint bids for procurement of various medical supplies and issue guidance on using the public procurement framework in the emergency situation related to the COVID-19 crisis (European Commission, 2020[59]).

Many private international standard setting organisations are also providing no-cost public access to relevant standards to promote supply of critical products. For example, the International Organisation for Standardization (ISO) has made available 28 ISO standards related to medical devices (ISO, 2020[60]), and has co-ordinated with the International Electrotechnical Commission (IEC) to make standards for critical care ventilators freely available (IEC, 2020[61]). The American Society for Testing and Materials (ASTM) allows access to 24 standards used for personal protective equipment including face masks, medical gowns, gloves, and hand sanitizers (ASTM, 2020[62]). In reaction to the pandemic, the International Medical Device Regulators Forum (IMDRF) published a list of standards indicating how to apply them in different jurisdictions including the EU, Australia, Brazil, Canada, the People’s Republic of China, Japan, the Russian Federation, Singapore, South Korea and the US (European Commission, 2020[63]). These efforts can help countries with limited prior production or import of critical products to rely on international standards to increase their availability. For instance, in Chile, a public-private initiative has enabled the domestic production of ventilators in response to the emergency by basing their technical specifications on ISO and IEC standards (SocialLab, 2020[64]).

Common standards are also at the basis of multilateral mechanisms supporting the acceptance of testing procedures and authorisations of critical products such as disinfectants and other biocides. For instance, the OECD Guidelines for the Testing of Chemicals allow countries to co-operate and harmonise testing on the safety and effectiveness of chemicals including disinfectant products such as hand sanitisers and wipes. While there is yet no similar system for authorisations of disinfectants, work has started to facilitate the exchange between countries of parts of their review of the authorisation dossiers (Diderich and Poret, 2020[65]).

Recognising conformity assessment procedures such as testing conducted by partner countries to facilitate regulatory delivery

Conformity assessment procedures can be particularly costly and burdensome for companies and administrations. Indeed, in normal times already, most trade concerns raised by countries about potentially burdensome measures of other countries in the WTO TBT Committee are about conformity assessment procedures, and in particular testing and certification (Karttunen and McDaniels, 2016[66]). In times of crisis when delays in trade flows can be especially harmful, such procedures can be seen as unnecessarily burdensome. Typically, several WTO members have notified actions to streamline certification and related conformity assessment procedures for PPE and other medical goods in response to the pandemic (WTO, 2020[35]). In the European Union, in particular, where the rules for the design, manufacturing and placing on their PPE market are already the same across all EU members,37 the main barrier to their trade are the procedures that companies need to undergo to demonstrate that their PPE conform to these rules. In response to this, the European Commission adopted a specific Recommendation on conformity assessment and market surveillance procedures within the context of the COVID-19 threat.38 This recommendation encourages all EU conformity assessment bodies to prioritise assessment of PPEs necessary for protection in time of COVID-19, and recalls the possibility for Member States to authorise derogations from conformity assessment procedures in certain special circumstances set forth in the Medical Devices Directive and Medical Devices Regulation.

The recognition of conformity assessment procedures facilitates regulatory delivery by expediting administrative procedures (OECD, 2017[9]).39 A country can choose to single-handedly recognise another country’s procedures, allowing its businesses to save time and resources by not undergoing the same procedures several times. Such unilateral recognition can be a flexible and rapid option for countries, without the need to negotiate with any other authorities. This is a particularly useful tool during a crisis when a mutual recognition agreement does not pre-exist and there is no time to negotiate one. It is also an option that helps maintain a certain level of regulatory standard (by opposition to removing the procedures all together). Typically, in response to the health crisis and to secure the availability of critical medical products, some governments have opted to unilaterally recognise / uphold technical standards for medical devices issued by competent authorities in other jurisdictions.

As such an example, in April 2020 the US FDA waived certain regulatory requirements to authorise healthcare personnel to use the disposable respirators (masks) that met requirements approved in other countries, even if not approved by the National Institute for Occupational Safety and Health (NIOSH) (US Food and Drug Administration, 2020[67]). Health Canada has set up simplified importation and sale procedures on medical devices necessary for use in relation to COVID-19, if they have been granted market approval by a foreign regulatory authority (Health Canada, 2020[68]). The UK Medicines and Healthcare products Regulatory Authority allows to reduce re-testing of medicines imported to the UK where this would significantly delay certification and batch release, as long as the laboratory of the third country manufacturer would have been inspected by an EU inspectorate or mutual recognition partner and granted good manufacturing practice (GMP) approval for this work (MHRA, 2020[69]).

Where they pre-exist, mutual recognition agreements (MRAs) can facilitate the availability of medical products that are essential for the response to the crisis and normally subject to regulations, including pharmaceuticals. Indeed, by eliminating duplicative inspections throughout all countries involved in the agreement, MRAs can help national regulators save resources that can then be redirected, for example, into medicines review and approvals, reducing the time needed to get essential medicine to the market (Goldberg, 2020[70]).

For example at the EU level, medicinal products that have a national marketing authorisation (authorised in one Member State) can apply for authorisation to be marketed in any other EU/EEA Member State (European Medicines Agency, 2016[71]). In addition, the EU has a number of mutual recognition agreements with third countries, facilitating market access of medicines and medical products, through sharing of information about inspections and waiving batch testing of products on import into their territories.40 In the context of COVID-19, the EU Co-ordination group for Mutual recognition and Decentralised procedures (CMDh) authorised the use of zero-day mutual recognition procedure to expand national marketing authorisations to new Member States who need COVID-19 medicinal products (EU, 2020[37]). EU authorities also facilitate continuous exchange of information between authorities on device conformity, availability and reliability, among others. Recognition also plays a role in the EU guidance on COVID-19 diagnostic (European Commission, 2020[72]), and the EU approach to improve testing schemes notes that tests applied should be of an acceptable quality and carried out so that there is mutual acceptance of test data within and among Member States (European Commission, 2020[33]).

In the context of the crisis, these co-operation mechanisms have been complemented with virtual means, such as the possibility of checking compliance with standards and regulations by remote or electronic means to alleviate the costs and challenges of physical presence (WTO, 2020[35]). While this may proceed from a unilateral decision, the integration of supply chains and international benefits of recognised conformity assessment procedures highlight the value of aligned decisions in this area. If sped up by the crisis, the uptake of virtual means to show or check compliance across countries proceeds from a deeper trend towards electronic certification as illustrated by the e-Phyto Solution set up by the International Plant Protection Convention.41

 IRC enables the interoperability of essential services and cross-border activities

The impact of the COVID-19 crisis is far-reaching. While domestic regulatory responses are vital to, inter alia, support the continued delivery of essential services, in areas with a strong transboundary dimension – typically in networks industries there is a significant need for cross-country co-ordination to ensure their continued interoperability during the crisis. In these sectors, incompatible domestic solutions and lack of collaboration to address challenges may compromise the cross-border effectiveness of the network as a whole. This is the case for instance of telecommunications, air travel, maritime transport and ports, and postal services. Similarly, once countries under social–distancing measures and lockdowns gradually resume activities, co-ordinated regulatory action will be needed to restart operations in these interconnected sectors.

Telecommunications is a cross-border sector that has been put under strain during the crisis as virtual connectivity needs increased in response to social-distancing and lockdown measures. This calls for collaboration to secure that operators can cope with the increased demand on network capacity while securing network resilience, continuity of operations and access (OECD, 2020[73]). For example, as a precautionary measure the European Commission and the Body of European Regulators for Electronic Communications (BEREC) have set up a special reporting mechanism to monitor the internet traffic situation in each Member State to be able to respond to capacity issues (European Commission and BEREC, 2020[74]). Governments can also co-operate to ensure that logistical and supply chain allow network operators to access new hardware and consumables needed to repair outages or upgrade their capacity (OECD, 2020[73]).

By contrast, the spread of COVID-19 has had significant negative implications on international transportation. Travel restrictions imposed in several countries to curb the spread of the virus and the decrease in travel demand significantly impacted the operations of civilian and cargo air companies. Preliminary estimates by the International Civil Aviation Organization (ICAO), show that the COVID-19 outbreak could cause an overall reduction of 47 to 58% of seats offered by airlines during the first half of 2020, compared to originally-planned.42 Transport by sea, and particularly container shipping, has also been affected albeit in much less drastic ways than air transport, with global container trade volumes declining by 8,6% in February 2020 compared with the same month of 2019 (ITF, 2020[75]).

Aviation is a sector where regulatory co-operation is key to guarantee passengers safety and to avoid redundant administrative procedures across countries. For example, air transportation relies heavily on requirements around expiration of licences and/or certifications, and safety inspections. As performing on-site visits became increasingly difficult due to the crisis, the European Union Aviation Safety Agency (EASA) announced the use of adapted procedures to maintain the oversight level necessary for safe operations, including flexibility around the suspension or limitation of certificates.43 In line with EASA, the UK Civil Aviation Authority exempted all operators, aircrew, instructors, examiners engaged in commercial air transport, along with aircraft maintenance licence holders and air traffic controllers, from the normal validity periods for licences, certificates and ratings that expire before the 31 October 2020.44 Other domestic regulators have followed with similar measures that guarantee the continued operation of services and will facilitate the restart of air travel once restrictions are lifted and demand raises.

Air transportation operators are under particular pressure to apply strict and specific processes to limit the spread of the virus among passengers. Internationally co-ordinated approaches in this area are particularly important to ensure that aviation companies comply with the same level of protection wherever they operate. The Collaborative Arrangement for the Prevention and Management of Public Health Events in Civil Aviation (CAPSCA) brings together all international, regional, national and local civil aviation organizations in order to combine efforts and develop a co-ordinated approach to public health risks such as pandemics.45 CAPSCA has centralised country, international organisation and other stakeholders’ COVID-19 initiatives related to civil aviation to provide easy access.46 In addition, all aviation-specific guidelines relevant for the COVID-19 crisis are consolidated in a single web portal clarifying what States and stakeholders can do to guarantee safety of international air travel and to communicate effectively throughout the outbreak.47 In particular, the site clarifies that States have the obligation to base all measures restrictive of air travel on a risk assessment;48 States should designate a focal point of contact for communication with other States and with the WHO regarding the implementation of WHO International Health Regulations.49

International maritime transport also calls for a strong co-ordinated response to prevent the spread of the virus within ships. Various incidents of COVID-19 outbreaks on cruise and military ships across the world have indeed drawn attention to the high risks of contagion between passengers and staff in the confined spaces of ships at sea.50 These incidents have stressed the strong need for internationally co-ordinated responses, due to the many nationalities of people on board and the global ramifications that the disembarking of passengers with the virus may have (Nakazawa, Ino and Akabayashi, 2020[76]). To prevent such risks while maintaining essential maritime transportation, particularly to ensure the availability of shipping services to the commerce of the world, the International Maritime Organisation has worked on protecting seafarers from contracting the virus and guaranteeing all personnel on ships and airports are considered as key workers that can therefore cross borders. 51

Similarly, the interdependence of financial markets advocates for a co-ordinated response from financial regulators and supervisors to secure financial stability and minimise the risk of market fragmentation from the COVID-19 crisis. As made evident by the 2008 Global Financial Crisis, the connections between far-flung markets raise concerns for the systemic impact of failure of cross-border financial institutions, including banks. The gaps highlighted in 2008 were met with a new system for global co-ordination among domestic and international financial regulators and supervisors (Moloney et al., 2015[77]) The COVID-19 crisis has led to an array of national responses. Only for the banking sector, the Institute of International Finance (IIF) reports over 300 prudential regulatory measures implemented between March and early April 2020 (IIF, 2020[78]). To tackle the risk of fragmentation that the national responses may generate, co-ordination through international organisations has been enhanced to oversee the continued implementation of recent G20 financial reforms in response to the crisis (OECD, 2020[79]). The Financial Stability Board (FSB) has delivered principles to maximise the benefit of a co-ordinated policy response and is supporting countries providing financial stability risk assessment, co-ordinating financial policy responses and serving as a platform for information sharing between its members, the International Organization of Securities Commissions (IOSCO), the Basel Committee on Banking Supervision (BCBS), the International Association of Insurance Supervisors (IAIS) (FSB, 2020[80]).

Looking ahead, a co-ordinated regulatory approach will be needed to ease social-distancing measures and restart activities in sectors with strong cross-border interdependencies. The Joint European Roadmap towards lifting COVID-19 containment measures acknowledges this and focuses on recommendations for co-ordinated action between the Member States to restart economic and social activities (European Commission, 2020[33]).52 Furthermore, a common regulatory approach could help countries that plan to rely on mobile applications (apps) to support lifting of containment measures by tracing the spread of the virus. Beyond the debates that affect their use (see the other contributions of the Regulatory Policy Division on this topic),53 such apps would deliver better on their potential if they provided information on the spread of the virus across borders. This can only happen if countries share similar standards to operate the systems and trust in the reliability of their respective infrastructure. This notably involves that they agree on similar guarantees of privacy for citizens and businesses. The EU provides a useful example of guidance applicable throughout the EU. It issued guidance to Member States and app developers on features and requirements that apps developed to track COVID-19 should meet to ensure compliance with EU privacy and personal data protection legislation (European Commission, 2020[81]) (European Commission, 2020[82]).

 Institutional set up for IRC

There are various institutional set-ups to support countries co-ordinate their regulatory responses to the crisis across jurisdictions, i.e. the IRC mechanisms highlighted above. These institutional arrangements are important to enable IRC over time, particularly during periods of crisis, when there is no time to establish new ambitious co-operation frameworks and think carefully of the appropriate mechanisms. They are critical elements of the resilience of regulatory frameworks. One way to understand the variety of IRC organisations is provided in Figure 1, which structures them around the national, bilateral, regional and the multilateral level. If anything, the current crisis has brought to light the roles of these various levels – in particular of the national and international level – and the tensions / dynamics from their interaction.

At the international level, policy makers have access to a wealth of regional and multilateral platforms. These platforms are the main multilateral co-operation mechanism used by countries for the past century or so. While the approach is more than a century old, the global rulemaking landscape has been very dynamic (in particular in the past 30 years) with multiple actors - inter-governmental (IGOs), trans-governmental (TGNs) and private - and a fast-growing body of norms and standards (OECD, 2019[83]). Countries are, on average, members of 50 IOs (OECD, 2013[11]) and there are some 144 networks of regulators that operate along traditional intergovernmental organisations (Abbott, Kauffmann and Lee, 2018[84]). The OECD already noted back in 1994 that countries were caught in “a web of formal and informal intergovernmental regulatory relationships” that “simultaneously empowers and constrains governments with respect to their ability to solve problems through regulation” (OECD, 1994[85]). The essential role played by IOs in addressing the current global crisis has been exemplified in the media scene by the WHO interventions. Yet, it is not the only active IO currently supporting a range of policy makers and stakeholders.

In these times of crisis where countries are turning inward, the multilateral system provides a very powerful mechanism to underpin collective action and address the global (health, social, economic) crisis. It is however under heavy criticisms for its sheer complexity. Transparency, evidence-based practices and co-ordination across players are essential to underpin effective and trustworthy international rulemaking. By participating actively in these IOs, country representatives and other stakeholders critically contribute to the quality and relevance of the international rules to best address the global challenges of today, while shaping them so they achieve their own national priorities. After all, the national and international levels are intrinsically intertwined.

Indeed, countries can do a lot at the national level to improve the coherence of their regulatory frameworks with the international environment (for example by respecting international rules that they have themselves contributed to establish through multilateral consensus-based processes) and build trustworthy institutions that can form the foundation of co-operation arrangements. Conversely, recent examples have shown that unilateral decisions and rules adopted at national level may threaten co-ordination (for example by deciding to unilaterally close borders or impose export restrictions). There is a strong asymmetry in this relation between the national and international level (which is largely the emanation of national governments): it takes all partners to build a consensus but only one to threaten co-ordination. The current crisis shows that the multilateral system cannot function effectively without strong country engagement.

This section discusses the institutional arrangements that can enable a co-ordinated regulatory response to the COVID-19 crisis. It describes the landscape of international organisations (IOs), their activities, responsibilities, and recent efforts to support their constituencies face the pandemic. Because of the intrinsic reliance of the international level on domestic processes, the section then identifies the roles and governance of IRC at national level. Both sub-sections establish the common practices, highlight their relevance for the current situation and identify areas of challenges where further improvement could be brought as a result of the spotlight put by the crisis on the need for international co-ordination.

Figure 1. Different organisational levels of IRC

Source: OECD IRC Guidance (forthcoming).

 International organisations in support of information exchange and common regulatory approaches

IOs play a crucial role to bolster and complement national institutions by promoting and developing common solutions at the international level. At the regional / plurilateral and multilateral level, a number of normative organisations provide for an opportunity to co-operate on rules among their constituency and beyond national boundaries. They can be differentiated from other forms of international co-ordination by their core task, i.e. to prepare the grounds for and produce common rules, by opposition to discussion fora, financial institutions or capacity building initiatives.

Systematic evidence collected by the OECD as part of the Partnership of International Organisations for Effective International Rulemaking (IO Partnership) shows that such IOs contribute to international rulemaking by offering platforms for continuous dialogue on and anticipation of new issues; establishing a common language; facilitating the comparability of approaches and practices; developing international legal and policy instruments; and, in a few (much more limited) cases, by offering enforcement and dispute resolution mechanisms (OECD, 2016[86]). This is clearly illustrated in Figure 2., which highlights the number of IOs (from a sample of 50 interviewed by the OECD in 2015) that carry out the various activities spanning the rulemaking cycle (from data collection to crisis management).

In their everyday work, IOs first and foremost act as data hubs. They provide the framework to “orchestrate” the sharing of evidence among their constituencies in their respective policy areas in various forms (raw, compiled in databases, analysed in thematic or country reports). The current crisis is no exception. Practically all normative IOs, including the OECD, have established a COVID-19 dedicated website that serves as platform for information exchange in their respective mandate (see list in Annex). Beyond these public websites, they also provide a safe place among members to exchange on their respective measures and discuss common position.

Figure 2. The core rulemaking activities of IOs

Source: (OECD, 2016[20]).

The WHO is emblematic of this role. The organisation compiles and disseminates health statistics that are essential to evaluate health programmes and make recommendations with respect to international health matters. The WHO’s International Health Regulations (IHR) provide an overarching legal framework that defines countries’ obligations in handling acute public health risks that have the potential to cross borders. The IHR “are the sole binding global legal instrument dedicated to the prevention and control of the international spread of disease(Burci, 2020[87]). Under the IHR, the WHO acts as a central co-ordinating body for addressing the pandemic, receiving notifications on outbreaks and disseminating information to help scientists address an epidemic at the global level (Box 3).

Box 3. WHO International Health Regulations – the legal framework underpinning exchange of information across members

The International Health Regulations (IHR) are an international legal instrument that is binding on 194 countries across the globe, including all the Member States of WHO. Their aim is to prevent, protect against, control and respond to the international spread of disease while avoiding unnecessary interference with international traffic and trade. They are also designed to reduce the risk of disease spread at international airports, ports and ground crossings.

The IHR set an extensive legal framework to ensure exchange of information between countries on public health emergencies, with the WHO centralising the information and thus facilitating access to it. They indeed require countries to notify WHO of all events that may constitute a “public health emergency of international concern” (PHEIC), and to respond to requests for verification of information regarding such events. Countries also have the obligation to report to WHO, as far as practicable, evidence of a public health risk identified outside of their territory which may cause international disease spread, as manifested by exported or imported human cases, vectors which carry infection or contamination, or goods that are contaminated.

States parties to the IHR have delegated to the Director-General the authority to determine whether an event constitutes a PHEIC in accordance with the criteria and procedure set out in the Regulations. In arriving at this determination, the Director-General takes into account several elements, including the advice of an Emergency Committee composed of experts.

WHO’s response to a PHEIC includes temporary recommendations concerning appropriate public health responses for application by the countries affected by such an emergency, as well as by other States and by operators of international transport. Standing recommendations indicating the appropriate measures for routine application for specific ongoing public health risks may also be issued

Source: OECD/WHO (2016), “International Regulatory Co-operation and International Organisations: The Case of the World Health Organization (WHO)”, OECD and WHO, www.oecd.org/gov/regulatory-policy/WHO_Full-Report.pdf.

Beyond the WHO, a wide range of IOs have refocused their attention to cater for the urgent data need of their constituencies to deal with the crisis. The OECD compiles real time data and analysis on the multifaceted consequences of the global crisis, from health to education, employment and taxes.54 The OIE compiles data from Members on any outcomes of investigation in animals to detect infectious with SARS-CoV-2.55 WTO is making available notifications of COVID-related measures56 and has issued a series of information notes on COVID-19 and world trade. 57 The World Tourism Organization has carried out an impact assessment of the COVID-19 crisis on the tourism sector.58 The Council of European Energy Regulators allows energy regulators to share notes on their respective national measures to address the COVID-19 induced decrease in energy demand; as well as to share practices on how to support vulnerable customers.59 The FAO has developed a Big Data tool on food chains under the COVID-19 pandemic that gathers, organises and analyses daily information on the impact of the COVID-19 pandemic on food and agriculture, value chains, food prices, food security and undertaken measures. As stated on the FAO website, the tool ultimate aim is to provide countries with facts and information on how the pandemic is impacting the food chains to build their decisions.60 WCO’s Customs Enforcement Network Communication Platform (CENcomm) allows customs worldwide to share intelligence on fake medical supplies and medicines (WCO, 2020[88]). Examples could be multiplied and apply to the range of various international organisations that countries participate in.

Beyond data collection, the crisis has shown the responsiveness of IOs to highlight and / or adapt their normative instruments to support their constituencies in coping with the crisis. The dedicated WHO technical guidance website now includes specific Guidance for laboratories shipping specimens to WHO reference laboratories that provide confirmatory testing for COVID-19 virus61, as well as Guidance on infection prevention and control62. The WHO has also issued key considerations for repatriation and quarantine of travelers63, advice to the public on when and how to use masks64 and advice to health workers about their rights, roles and responsibility65. The OIE has highlighted the potential use of veterinary labs to address the growing need for facilities to conduct diagnostic testing of human samples for COVID-19 and made available high level guidance for veterinary laboratories working with public health services to support testing of human samples for COVID-19.66 This is an important example of how innovative cross-sectors thinking can help to address the current pandemic.

Beyond the health sector, a large number of IOs have developed guidance adapting their traditional tools to the context of the epidemics – either advising their constituencies on how to deal with the epidemics in their area or the related global social and economic crisis. The OECD provides tailored guidance to help countries during the crisis in its various policy areas, including on maintaining regulatory quality in times of crisis. The International Labour Organization (ILO) has prepared a Prevention and Mitigation of COVID-19 at Work Action Checklist that offers a collaborative approach to assess COVID-19 risks as a step to take measures to protect the safety and health of workers.67 The International Maritime Organization (IMO) provides various advice and guidance to facilitate maritime trade and preserve the health of seafarers.68 ICAO has developed a number of “quick reference guides” to provide guidance of a particular subject area in addressing COVID-19 related risks to the continuity of aviation business and operations.69 Interpol has developed guidelines on how to protect law enforcement and first responders.70 The Commonwealth has developed Guidelines on sport, exercise and physical activity71 and Sport policy during the coronavirus pandemic72. WCO has developed guidance on a number of issues to facilitate movement of essential goods across borders. BIPM is working with National Metrology Institutes on validation, calibration and verification of measurement instruments relevant for a range of COVID-19 essential products and to develop protocols for organising scientific comparisons to underpin antigen and vaccine testing.

While IGOs have embraced their advisory role to States, many non-governmental organisations, including private and non-profit, have also stepped up to service their constituency – sometimes in close co-ordination with inter-governmental processes. International private standard setting organisations, such as ISO and ASTM international, are providing free access to their standards of relevance to the production and testing of various essential protective equipment (including masks, medical gowns, gloves, and hand sanitizers) and medical devices (such as ventilators). Professional organisations collect practices across their wide membership of “operators” to consolidate good practices and voluntary guidance. Examples are manifold, some are reported in Box 4. In addition, civil society – such as Oxfam or Médecins Sans Frontières – have stepped up their action to complement the work of traditional IOs and facilitate the implementation of international guidance in developing countries.

Box 4. Examples of COVID action by non-governmental organisations
  • The International Union of Railways (IUC), the worldwide professional association representing the railway sector (established in 1922) has developed guidance for Railway operators to deal with the crisis based on practices collected from members.

  • The Global System for Mobile Communications Association (GSMA), the organisation representing the interests of mobile operators worldwide has developed 11 Regulatory Recommendations to Sustain Connectivity during the COVID-19 Crisis.

  • IATA, the association of airlines companies has developed an Emergency Response Plan and Action Checklist for use by air carriers in the event of a public health emergency and a series of guidelines for airline staff.

  • The International Road Transport Union (IRU), the association of road transport organisations has issued a number of recommendations and guidance aimed at various transport means (for example recommendations for freight drivers and another set of recommendations for bus drivers).

In a more limited number of cases, the IOs have the mandate to support their members in managing crisis (Figure 2). This is actually the case of the WHO, which is mandated to undertake emergency action to face pandemics. The Organisation’s role in the area of crisis management has become more technical and operational in nature (Berman, 2020[89]). Also, WHO intervenes on international health crisis by co-ordinating with other agencies in the context of a humanitarian crisis. The Organisation’s work in emergencies is guided by the Emergency Response Framework. In 2016, responding to lessons learnt from the Ebola crisis, the WHO underwent a reform of its emergency capacities including the establishment of the Emergencies Oversight and Advisory Committee (OECD/WHO, 2016[25]). The current crisis is undoubtedly testing again the effectiveness of the international health system and providing it again an opportunity to evolve and adapt based on lessons learnt from current shortcomings.73 In March 2020, the WHO created a new structure – the new Division of Emergency Preparedness - to improve the responsiveness to emergency situations, and in particular to prevent and mitigate the impact of outbreaks and other health crises.74

Despite its support to regulatory co-operation across borders, the multilateral system is once again under heavy criticisms. It is deemed incoherent, bureaucratic, and non-transparent.75 This perception emanates largely from the complexity of the system. The multiplicity of IOs and instruments and their linkages are difficult to navigate for users, including policy makers and legislators that may have to implement them in their own jurisdictions. With a view to improve the understanding of the landscape of international normative institutions, the IO Partnership launched by the OECD in 2014 brings together some 50 secretariats of IOs to promote and discuss the conditions for greater quality, effectiveness and impact of international rules, regardless of their substantive scope. This collective effort has led to an unprecedented collection of information and exchange of practices on the rulemaking activities of IOs. The resulting 2019 Brochure on The Contribution of International Organisations to a Rule-Based International System sheds light on the functioning of the international rulemaking (OECD, 2019[83]). It acknowledges the complexity of the system – in particular, the sheer number and variety of types of international organisations and of international instruments. This system reflects the increasing complexity of policy issues that policy makers have to face and their inherent dependence.

Addressing the COVID-19 crisis requires urgent and co-ordinated action across policy fields from the global governance architecture as a whole. The current crisis involves addressing the pandemic, while dealing with the educational and social repercussions of stringent confinement policies, and maintaining heavily hit economies afloat. At the international level, as is the case nationally, these various aspects call on the competence of a wide range of different policy communities – see for example the multiplication of joint calls by heads of IOs highlighting the strong links between the pandemics and various policy areas, such as food, trade, aviation76. Both at international and national levels, more could be done to foster co-operation among policy communities, as recalled inter alia by the existence and the wording of the joint ICAO/WHO statement: “Cross-sector collaboration at the national level is also important, and in this regard, States are reminded to coordinate between aviation and health authorities and to establish National Facilitation Committees that comprise all relevant groups, in line with ICAO guidelines”. While IOs engage in a multiplicity of co-operation initiatives with other IOs, these tend to remain informal or less stringent co-operation arrangements for which effectiveness and impacts are difficult to assess (OECD, 2019[83]). Ultimately and unfortunately, IOs often reproduce the silo approaches across policy communities and stakeholders that exist at national level.

Clear, evidence-based, coherent and high quality international rules are critical for an effective global response to COVID-19. Common complaints against IOs include lack of credibility or partiality of the information collected. Indeed, as major data hubs, IOs have a key role to play to ensure the quality of the information that they collect. In this respect, one may question the control mechanisms that IOs are able / allowed to establish to ensure the quality of the information. IOs collect a mix of information related to the use of their normative instruments, both quantitative and qualitative. This information may be provided by members through voluntary or mandatory reporting mechanisms. Depending on their mandate, the IO secretariats act as “pure” repository of information provided by members, or may engage in active data gathering and carry some quality control of the information mostly through review process and internal quality checks (OECD, 2019[83]). Mostly, however, IOs depend on the information provided by members, which determines their availability and quality (Figure 3).77 This is typically the case of the WHO, whose legal authority to independently obtain information and to compel states to provide information is limited – in particular the WHO does not have the authority to undertake inspections and verify information in a member country (Berman, 2020[89]).

Figure 3. Mechanisms used by IOs to track implementation of their instruments

Source: (OECD, 2016[20]).

There is, therefore, a shared responsibility of the IO secretariats and their members to improve the quality and comparability of the information that is shared. While, it will always be difficult for IOs to protect against the strategic / non-cooperative use of information (especially in the short term perspective that the COVID-19 crisis imposes), the strengthening of institutional mechanisms and good regulatory practices such as stakeholder engagement, regular evaluation, evidence-based discussions can help improve the quality of the information and normative processes over time. There is also a direct link between the capacity of the IO secretariat (in a broad sense, including its qualification, resources and independence from members) and its ability to play its consensus-building, quality control role. Indeed, (OECD, 2016[86]) highlights the wide disparity across IOs in terms of size of secretariats and related roles – the bigger the size of the secretariat, the more it is able to go beyond organising meetings and serving as a repository of information. There is nevertheless also a responsibility of IOs to allocate the resources and focus on core responsibilities.

 IRC needs strong embedding in national regulatory frameworks

As already illustrated above, the roots of the multilateral system lie very much at the national level. The international level is in many instances the emanation of the national level (clearly in the case of inter-governmental organisations and via the support of their constituencies for other types of IOs). In addition, a solid regulatory policy framework domestically is a sine qua non condition for a jurisdiction to establish ambitious bridges with foreign jurisdictions and IOs. While some of the linkages between the national and international levels may have weakened – and countries raise scepticism about the effectiveness IO action – stronger national ownership of international processes (in the respect of the consensus-based approach and of the integrity of IO processes) can go a long way to regain trust in international bodies and improve the current international rulemaking system. This requires political leadership, resources and capacity.

To make the best of the multilateral system, particularly in times of crisis when rapid action is needed, there is a need for systematic consideration of international expertise and rules as part of domestic rulemaking. Currently, however, a number of countries cannot capitalise on IRC and their participation in IOs for lack of internal whole-of-government policies, frameworks or strategies that promote IRC operation and international engagement more broadly. This is illustrated by the 2018 OECD Regulatory Policy Outlook, which highlights the limited number of countries with an explicit cross-government policy on IRC (Figure 4), and the related fragmentation of oversight functions (notably between the regulatory oversight body, the institution responsible for trade policy and the ministry of foreign affairs) (OECD, 2018[19]). This often combines with a lack of standardised approaches and guidance on how ministries and regulators can deal with international instruments and their engagement in international organisations. In addition, the 2018 Regulatory Policy Outlook, as well as the Report on Better Regulation Practices across the European Union, note the need for greater sharing and use of information between the international and national levels from regulatory evaluation processes as an important avenue to strengthen the evidence base and capitalise better on the international intelligence (OECD, 2018[19]) and (OECD, 2019[90]).

Figure 4. Number of countries with an explicit, published policy or a legal basis on IRC

Note: Data for OECD countries is based on the 35 OECD member countries, the European Union, and three accession countries.

Source: (OECD, 2018[19]) and Indicators of Regulatory Policy and Governance Survey 2017, https://oe.cd/ireg.

During the emergency, mechanisms typically exist for information sharing between domestic authorities, WHO and other relevant international organisations. A number of countries set in place emergency bodies to co-ordinate the national response to the virus that include responsibilities for international co-ordination. While key in the immediate response to the crisis, to fully reap the benefits from IRC a stable policy and on-going mechanisms need to be established to these effects. More systematic consideration of the international environment in domestic rulemaking requires in many cases a significant change in the regulatory culture of countries. This change involves understanding and embedding a routine “beyond the border” perspective in rulemaking to avoid the automatic inward looking reaction. Such a cultural shift requires strong political will, leadership and dedicated attention to establishing a whole of government strategy for IRC.

IRC has important implications for the activities of regulators and of their oversight bodies. This involves the more systematic review and consideration of foreign and international regulatory frameworks of relevance when regulating and the assessment of how regulatory measures impact and fit within the broader cross-border management of the issue to address. Practically, as identified in the forthcoming OECD Best Practice Principles on International Regulatory Co-operation (GOV/RPC(2020)3), it requires from policy makers that they embed a stronger international lens in their regulatory management tools (such as the regulatory impact assessment processes, the ex post evaluation and stakeholder engagement processes) (Box 5).

This work highlights the importance for policy makers and regulators to embed mechanisms and process that help them gather evidence and expertise that may go beyond their own jurisdiction. In the context of the COVID-19 crisis, when time is tight, having such processes in place can ease the critical resource constraints faced by the administration and help catalyse the efficiency benefits of IRC. Not only can countries benefit from the availability of evidence and the lessons from the jurisdictions ahead of the contagion curve to refine their reaction to the crisis, having joint instruments and mechanisms in place with other jurisdictions can allow quicker reaction and international co-ordination to preserve the necessary interoperability of critical infrastructure and supply chains. The COVID-19 has showed the importance of building such IRC mechanisms; they are the critical pillars of resilient regulatory systems worldwide.

Box 5. Embedding IRC throughout the domestic rulemaking, extract of the draft OECD Best Practice Principles on International Regulatory Co-operation (forthcoming)

The regulatory management tools (Regulatory Impact Assessment, stakeholder engagement and ex post reviews of regulation) provide important entry points in the rule-making process to consider the international environment in the development and revision of laws and regulations. The upcoming OECD guidance on IRC highlights in particular four practices to emphasise the international environment in domestic rulemaking.

  • Consider more systematically the intelligence accumulated in other jurisdictions on similar issues to inform the rationale and range of potential options

It is fairly rare that a new issue arises without any other jurisdiction and international organisation having had to deal with it. Gathering the intelligence around the incidence of the issue at stake and the approaches adopted by others can help build the body of evidence on the area under consideration, gather a greater range of options for action, and develop the narrative around the chosen measure.

  • Consider adopting international instruments and other relevant regulatory frameworks when developing or updating laws and regulations

International normative instruments are usually the results of significant evidence gathering and consensus building (including scientific). Using them in domestic legislation provides a strong driver for regulatory consistency internationally therefore reducing the opportunities for arbitrage and the costs for the regulated entities of having to comply with multiple requirements.

  • Listen to stakeholders beyond own jurisdiction to gather information about the implications of domestic regulation

Engagement of foreign stakeholders in regulatory processes can help raise awareness for regulatory approaches in other jurisdictions or provide information about unintended impacts for third parties of maintaining the same or different regulatory approaches.

  • Assess the range of impacts (including on international flows and outside the jurisdiction) of laws and regulations once they are adopted and their divergence with international good practice.

Regulatory impact assessment processes can provide the opportunity to evaluate the costs and benefits of applying or departing from international standards, as well as the potential impacts on parties outside of the national boundaries of new regulatory measures.

Source: OECD (Forthcoming), OECD Best Practice Principles on International Regulatory Co-operation, OECD, Paris.


[84] Abbott, K., C. Kauffmann and J. Lee (2018), “The contribution of trans-governmental networks of regulators to international regulatory co-operation”, OECD Regulatory Policy Working Papers, No. 10, OECD Publishing, Paris, https://dx.doi.org/10.1787/538ff99b-en.

[7] Alliance for Multilateralism (2020), We need strong global cooperation and solidarity to fight COVID-19 - Federal Foreign Office, https://www.auswaertiges-amt.de/en/newsroom/news/alliance-multilateralism-covid19/2333394 (accessed on 17 April 2020).

[62] ASTM (2020), ASTM Standards & COVID-19, https://www.astm.org/COVID-19/.

[4] Berglöf, E., G. Brown and J. Farrar (2020), A Letter to G20 Governments, https://www.project-syndicate.org/commentary/a-letter-to-g20-governments-by-erik-berglof-et-al-2020-04 (accessed on 16 April 2020).

[98] Berman, A. (2020), Between Participation and Capture in International Rule-Making: The WHO Framework of Engagement with Non-State Actors, SSRN, https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3434603.

[89] Berman, A. (2020), The World Health Organization and COVID-19: How Much Legal Authority Does the WHO Really Have to Manage the Pandemic?, 2020, https://cil.nus.edu.sg/the-world-health-organization-and-covid-19-how-much-legal-authority-does-the-who-really-have-to-manage-the-pandemic-by-dr-ayelet-berman/ (accessed on 14 May 2020).

[41] Bown, C. (2020), Covid-19: Demand spikes, export restrictions, and quality concerns imperil poor country access to medical supplies, Voxeu.

[99] Breeden, A. (2020), “How the Coronavirus Slipped Aboard a French Navy Ship - The New York Times”, New York Times, https://www.nytimes.com/2020/04/19/world/europe/france-navy-ship-coronavirus.html (accessed on 3 June 2020).

[34] Bryant, J. et al. (2020), “Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward”, Science Immunology, Vol. 5/47, p. eabc6347, http://dx.doi.org/10.1126/sciimmunol.abc6347.

[87] Burci, G. (2020), The Outbreak of COVID-19 Coronavirus: are the International Health Regulations fit for purpose?, https://www.ejiltalk.org/the-outbreak-of-covid-19-coronavirus-are-the-international-health-regulations-fit-for-purpose/ (accessed on 8 June 2020).

[100] Burci, G. and K. Daugirdas (2019), “Financing the World Health Organization: What Lessons for Multilateralism?”, International Organizations Law Review, Vol. 16/2, pp. 299-338, https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3434603.

[101] Burci, G. and J. Quirin (2018), “Implementation of the International Health Regulations (2005): Recent Developments at the World Health Organization”, ASIL, Vol. 22/13, https://www.asil.org/insights/volume/22/issue/13/implementation-international-health-regulations-2005-recent-developments (accessed on 26 September 2018).

[65] Diderich, B. and S. Poret (2020), Why is there a shortage of disinfectants during the COVID-19 crisis?, OECD Environment Focus, https://oecd-environment-focus.blog/2020/05/12/why-is-there-a-shortage-of-disinfectants-during-the-covid-19-crisis/ (accessed on 26 May 2020).

[31] EMA (2020), Mandate, objectives and rules of procedure of COVID-19 EMA pandemic Task Force (COVID-ETF), https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-covid-19-ema-pandemic-task-force-covid-etf_en.pdf (accessed on 16 April 2020).

[13] Esty, D. and D. Geradin (2000), “Regulatory co-opetition”, Journal of International Economic Law, Vol. 3/2, pp. 235-255, http://dx.doi.org/10.1093/jiel/3.2.235.

[37] EU, H. (2020), Questions and Answers on Regulatory Expectations for Medicinal Products for Human use during the COVID-19 Pandemic, European Commission, Heads of Medicines Agencies, and European Medicines Agencies, https://ec.europa.eu/health/sites/health/files/human-use/docs/guidance_regulatory_covid19_en.pdf.

[36] European Commission (2020), Commission Implementing Regulation (EU) 2020/466 of 30 March 2020 on temporary measures to contain risks to human, animal and plant health and animal welfare during certain serious disruptions of Member States’ control systems due to coronavirus disease (COVID-19), http://data.europa.eu/eli/reg_impl/2020/466/oj.

[59] European Commission (2020), Communication from the Commission Guidance from the European Commission on using the public procurement framework in the emergency situation related to the COVID-19 crisis, http://dx.doi.org/C/2020/2078.

[81] European Commission (2020), Communication from the Commission Guidance on Apps supporting the fight against COVID 19 pandemic in relation to data protection 2020/C 124 I/01, European Commission , Brussels, https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1587141168991&uri=CELEX:52020XC0417(08).

[72] European Commission (2020), Communication from the Commission: Guidelines on COVID-19 in vitro diagnostic tests and their performance C(2020) 2391, European Commission , Brussels, https://ec.europa.eu/info/sites/info/files/testing_kits_communication.pdf.

[58] European Commission (2020), Coronavirus: European standards for medical supplies made freely available to facilitate increase of production, https://ec.europa.eu/commission/presscorner/detail/en/ip_20_502 (accessed on 17 April 2020).

[29] European Commission (2020), Guidance on medical devices, active implantable medical devices and in vitro diagnostic medical devices in the COVID-19 context, https://ec.europa.eu/docsroom/documents/40607 (accessed on 22 April 2020).

[63] European Commission (2020), IMDRF Standards Checklist modified in scope of COVID-19, https://ec.europa.eu/docsroom/documents/40607 (accessed on 22 April 2020).

[33] European Commission (2020), Joint European Roadmap towards lifting COVID-19 containment measures, European Commission , Brussels, https://ec.europa.eu/info/sites/info/files/communication_-_a_european_roadmap_to_lifting_coronavirus_containment_measures_0.pdf.

[82] European Commission (2020), Recommendation on a common Union toolbox for the use of technology and data to combat and exit from the COVID-19 crisis, in particular concerning mobile applications and the use of anonymised mobility data C(2020) 2296 f, European Commission , Brussels, https://ec.europa.eu/info/sites/info/files/recommendation_on_apps_for_contact_tracing_4.pdf.

[74] European Commission and BEREC (2020), Joint Statement from the Commission and the Body of European Regulators for Electronic Communications (BEREC) on coping with the increased demand for network connectivity due to the Covid-19 pandemic., https://berec.europa.eu/eng/document_register/subject_matter/berec/others/9236-joint-statement-from-the-commission-and-the-body-of-european-regulators-for-electronic-communications-berec-on-coping-with-the-increased-demand-for-network-connectivity-due-to- (accessed on 20 April 2020).

[71] European Medicines Agency (2016), The European regulatory system for medicines.

[24] Evenett, S. (2020), Tackling Coronavirus: The Trade Policy Dimension, https://www.globaltradealert.org/reports/50 (accessed on 21 April 2020).

[45] FAO (2020), Agri-food markets and trade policy in the time of COVID-19, http://www.amis-outlook.org/ (accessed on 14 May 2020).

[97] FAO, O. (2019), A Tripartite Guide to Addressing Zoonotic Diseases in Countries Taking a Multisectoral, One Health Approach.

[8] FAO, WHO and WTO (2020), Joint Statement by QU Dongyu, Tedros Adhanom Ghebreyesus and Roberto Azevêdo, Directors-General of FAO, WHO and WTO, https://www.wto.org/english/news_e/news20_e/igo_26mar20_e.htm (accessed on 16 April 2020).

[46] Fernandes Guimarães, M. and A. Haniotis (2020), Covid-19: Now is the time for greater international collaboration, http://www.amis-outlook.org/news/detail/en/c/1152580/ (accessed on 14 May 2020).

[40] Fiorini, M., B. Hoekman and A. Yildirim (2020), Covid-19: Expanding access to essential supplies in a value chain world, Voxeu.

[80] FSB (2020), COVID-19 pandemic: Financial stability implications and policy measures taken, Financial Stability Board, https://www.fsb.org/wp-content/uploads/P150420.pdf.

[5] G20 (2020), Extraordinary G20 Leaders’ Summit Statement on COVID-19.

[96] G20 (2020), G20 Trade and Investment Ministerial Statement.

[47] G20 (2020), Ministerial Statement on Covid-19, G20 Extraordinary Agriculture Ministers Meeting.

[94] Gates, B. (2020), “Pour une approche globale de la lutte contre le Covid-19”, Le Monde, https://www.lemonde.fr/idees/article/2020/04/12/bill-gates-pour-une-approche-globale-de-la-lutte-contre-le-covid-19_6036352_3232.html#xtor=AL-32280270 (accessed on 16 April 2020).

[70] Goldberg, E. (2020), Regulatory Cooperation to Combat Public Health Crises, The Regulatory Review, https://www.theregreview.org/2020/04/27/golberg-regulatory-cooperation-combat-public-health-crises/ (accessed on 27 April 2020).

[1] Gomart, T. (2020), “La crise due au coronavirus est la première d’un monde post-américain”, Le Monde, https://www.lemonde.fr/idees/article/2020/04/08/thomas-gomart-la-crise-due-au-coronavirus-est-la-premiere-d-un-monde-post-americain_6035934_3232.html (accessed on 16 April 2020).

[44] González, A. (2020), A memo to trade ministers on how trade policy can help fight COVID-19 | PIIE, PIIE Trade and Investment Policy Watch, https://www.piie.com/blogs/trade-and-investment-policy-watch/memo-trade-ministers-how-trade-policy-can-help-fight-covid (accessed on 20 April 2020).

[17] Grimalda, G. (2020), Lessons for Global Cooperation from the COVID-19 Pandemic - International Development Blog, https://blogs.die-gdi.de/2020/04/01/lessons-for-global-cooperation-from-the-covid-19-pandemic/ (accessed on 16 April 2020).

[68] Health Canada (2020), Applications for medical devices under the Interim Order for use in relation to COVID-19: Guidance document, https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/interim-order-importation-sale-medical-devices-covid-19/guidance-medical-device-applications.html (accessed on 27 April 2020).

[48] Hoekman, B., M. Fiorini and A. Yildirim (2020), “COVID-19: Export controls and international cooperation”, in Baldwin, R. and S. Evenett (eds.), COVID-19 and Trade Policy: Why Turning Inward Won’t Work, Voxeu, https://www.globaltradealert.org/reports/53 (accessed on 14 May 2020).

[61] IEC (2020), IEC Webstore: Access to key standards for critical care ventilators, https://webstore.iec.ch/webstore/webstore.nsf/xpFAQ.xsp?OpenXPage&id=GFOT-BNAEXA (accessed on 17 April 2020).

[78] IIF (2020), An aerial view of the bank prudential regulatory response to COVID-19, http://dx.doi.org/Institute of International Finance.

[60] ISO (2020), COVID-19 Response: Freely Available ISO Standards, https://www.iso.org/covid19 (accessed on 17 April 2020).

[75] ITF (2020), Global Container Shipping and the Coronavirus Crisis.

[51] Karttunen, M. (2020), Transparency in the WTO SPS and TBT agreements : the real jewel in the crown, Cambridge University Press.

[66] Karttunen, M. and D. McDaniels (2016), “Trade, Testing and Toasters: Conformity Assessment Procedures and the TBT Committee”, Journal of World Trade, Vol. 50/3.

[43] Lim, H., L. Locks and D. McDaniels (2020), Facilitating trade to address Covid 19 crisis, https://www.linkedin.com/pulse/facilitating-trade-address-covid-19-crisis-aik-hoe-lim/ (accessed on 22 April 2020).

[57] Madzou, L. (2020), COVID-19: Is AI trustworthy enough to help us fight back?, WEF, https://www.weforum.org/agenda/2020/05/covid19-coronavirus-artificial-intelligence-ai-response/ (accessed on 27 May 2020).

[69] MHRA (2020), Exceptional GMP flexibilities for medicines imported from third countries during the coronavirus (COVID-19) outbreak: Guidance, https://www.gov.uk/guidance/exceptional-gmp-flexibilities-for-medicines-imported-from-third-countries-during-the-coronavirus-covid-19-outbreak (accessed on 27 April 2020).

[77] Moloney, N. et al. (2015), “Institutional Design: The International Architecture”, in Moloney, N., E. Ferran and J. Payne (eds.), The Oxford Handbook of Financial Regulation, Oxford University Press, Oxford, http://dx.doi.org/10.1093/oxfordhb/9780199687206.013.7.

[76] Nakazawa, E., H. Ino and A. Akabayashi (2020), “Chronology of COVID-19 cases on the Diamond Princess cruise ship and ethical considerations: A report from Japan”, Disaster Medicine and Public Health Preparedness, p. 1, http://dx.doi.org/10.1017/dmp.2020.50.

[22] OECD (2020), Beyond Containment:Health systems responses to COVID-19 in the OECD, https://read.oecd-ilibrary.org/view/?ref=119_119689-ud5comtf84&title=Beyond_Containment:Health_systems_responses_to_COVID-19_in_the_OECD (accessed on 8 April 2020).

[38] OECD (2020), COVID-19 and International Trade: Issues and Actions.

[2] OECD (2020), COVID-19: Protecting people and societies, https://read.oecd-ilibrary.org/view/?ref=126_126985-nv145m3l96&title=COVID-19-Protecting-people-and-societies (accessed on 16 April 2020).

[3] OECD (2020), Evaluating the initial impact of COVID-19 containment measures on economic activity, https://read.oecd-ilibrary.org/view/?ref=126_126496-evgsi2gmqj&title=Evaluating_the_initial_impact_of_COVID-19_containment_measures_on_economic_activity (accessed on 16 April 2020).

[27] OECD (2020), Flattening the COVID-19 peak: Containment and mitigation policies, https://read.oecd-ilibrary.org/view/?ref=124_124999-yt5ggxirhc&title=Flattening_the_COVID-19_peak-Containment_and_mitigation_policies (accessed on 8 April 2020).

[79] OECD (2020), Global Financial Markets Policy Responses to COVID-19, OECD, Paris, https://read.oecd-ilibrary.org/view/?ref=127_127003-tvl9kqbfy9&title=Global-Financial-Markets-Policy-Responses-to-COVID-19.

[73] OECD (2020), Keeping the Internet up and running in times of crisis, OECD, Paris, https://read.oecd-ilibrary.org/view/?ref=130_130768-5vgoglwswy&title=Keeping-the-Internet-up-and-running-in_times-of-crisis.

[10] OECD (2020), Regulatory Quality and COVID-19: Managing the Risks and Supporting the Recovery, OECD, Paris, http://www.oecd.org/gov/regulatory-policy/Regulatory-Quality-and-Coronavirus%20-(COVID-19)-web.pdf.

[21] OECD (2020), Review of International Regulatory Co-operation of the United Kingdom, OECD Publishing, Paris, https://dx.doi.org/10.1787/09be52f0-en.

[53] OECD (2020), Trade Facilitation and the COVID-19 Pandemic, OECD, Paris, https://read.oecd-ilibrary.org/view/?ref=130_130609-v8jn83j1j3&title=Trade-facilitation-and-the-covid-19-pandemic.

[23] OECD (2020), Trade interdependencies in COVID-19 goods, OECD, Paris, https://read.oecd-ilibrary.org/view/?ref=132_132706-m5stc83l59&title=Policy-Respone-Trade-Interdependencies-in-Covid19-Goods.

[90] OECD (2019), Better Regulation Practices across the European Union, OECD Publishing, Paris, https://dx.doi.org/10.1787/9789264311732-en.

[14] OECD (2019), Saving Costs in Chemicals Management: How the OECD Ensures Benefits to Society, OECD Publishing, Paris, https://dx.doi.org/10.1787/9789264311718-en.

[83] OECD (2019), The Contribution of International Organisations to a Rule-Based International System, OECD, Paris, https://www.oecd.org/gov/regulatory-policy/IO-Rule-Based%20System.pdf.

[92] OECD (2018), Good Jobs for All in a Changing World of Work: The OECD Jobs Strategy, OECD Publishing, Paris, https://dx.doi.org/10.1787/9789264308817-en.

[19] OECD (2018), OECD Regulatory Policy Outlook 2018, OECD Publishing, Paris, https://dx.doi.org/10.1787/9789264303072-en.

[20] OECD (2018), Review of International Regulatory Co-operation of Mexico, OECD Publishing, Paris, https://dx.doi.org/10.1787/9789264305748-en.

[9] OECD (2017), International Regulatory Co-operation and Trade: Understanding the Trade Costs of Regulatory Divergence and the Remedies, OECD Publishing, Paris, https://dx.doi.org/10.1787/9789264275942-en.

[86] OECD (2016), International Regulatory Co-operation: The Role of International Organisations, OECD Publishing.

[93] OECD (2014), “The crisis and its aftermath: A stress test for societies and for social policies”, in Society at a Glance 2014: OECD Social Indicators, OECD Publishing, Paris, https://dx.doi.org/10.1787/soc_glance-2014-5-en.

[15] OECD (2013), International Regulatory Co-operation: Case Studies, Vol. 1: Chemicals, Consumer Products, Tax and Competition, OECD Publishing, Paris, https://dx.doi.org/10.1787/9789264200487-en.

[11] OECD (2013), International Regulatory Co-operation: Addressing Global Challenges, OECD Publishing, Paris, https://dx.doi.org/10.1787/9789264200463-en.

[91] OECD (2010), OECD Employment Outlook 2010: Moving beyond the Jobs Crisis, OECD Publishing, Paris, https://dx.doi.org/10.1787/empl_outlook-2010-en.

[85] OECD (1994), Regulatory Co-operation for an Interdependent World, Public Management Studies, OECD Publishing, Paris, https://dx.doi.org/10.1787/9789264062436-en.

[25] OECD/WHO (2016), International Regulatory Co-operation and International Organisations The Case of the World Health Organization (WHO).

[50] OECD/WTO (2019), Facilitating Trade through Regulatory Cooperation: The Case of the WTO’s TBT/SPS Agreements and Committees, OECD Publishing, Paris/World Trade Organization, Geneva, https://dx.doi.org/10.1787/ad3c655f-en.

[28] Patel, C. and D. Salisbury (2020), The Hurdles to Developing a COVID-19 Vaccine: Why International Cooperation is Needed, Chatam House, https://www.chathamhouse.org/expert/comment/hurdles-developing-covid-19-vaccine-why-international-cooperation-needed (accessed on 11 May 2020).

[42] Pauwelyn, J. (2020), “Export Restrictions In Times Of Pandemic: Options And Limits Under International Trade Agreements”, SSRN Electronic Journal, http://dx.doi.org/10.2139/ssrn.3579965.

[18] Russack, S. and S. Blockmans (2020), How is EU cooperation on the Covid-19 crisis perceived in member states? | CEPS, CEPS, https://www.ceps.eu/ceps-publications/how-is-eu-cooperation-on-the-covid-19-crisis-perceived-in-member-states/ (accessed on 21 April 2020).

[64] SocialLab (2020), Un respiro para Chile, SocialLab, https://cl.socialab.com/challenges/unrespiroparachile (accessed on 28 April 2020).

[32] Stiglitz, J., A. Jayadev and A. Prabhala (2020), Patents vs. the Pandemic, Project Syndicate, https://www.project-syndicate.org/commentary/covid19-drugs-and-vaccine-demand-patent-reform-by-joseph-e-stiglitz-et-al-2020-04 (accessed on 11 May 2020).

[6] United Nations General Assembly (2020), Global solidarity to fight the coronavirus disease 2019 (COVID-19), A/RES/74/270.

[67] US Food and Drug Administration (2020), Letter of Authorization for Non-NIOSH-Approved Disposable Filtering Facepiece Respirators Manufactured in China, https://www.fda.gov/media/136664/download.

[95] US Food and Drug Administrator (2020), Emergency Use Authorization, https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#covidothermeddev (accessed on 16 April 2020).

[88] WCO (2020), Customs Enforcement Network Communication Platform (CENcomm), 2020, http://www.wcoomd.org/en/topics/enforcement-and-compliance/instruments-and-tools/cen-suite/cencomm.aspx (accessed on 27 May 2020).

[54] WCO (2020), WCO Secretariat Note How to establish and utilize essential goods lists during a disaster, WCO, Brussels, http://www.wcoomd.org/-/media/wco/public/global/pdf/topics/facilitation/activities-and-programmes/natural-disaster/covid_19/essential-goods-lists_guidance.pdf?la=en.

[55] WCO/WHO (2020), HS classification reference for Covid-19 medical supplies 2nd Edition, WCO, http://www.wcoomd.org/-/media/wco/public/global/pdf/topics/nomenclature/covid_19/hs-classification-reference_edition-2_en.pdf?la=en.

[56] WCO/WHO (2020), List of priority medicines for customs during COVID-19 pandemic, WCO, http://www.wcoomd.org/-/media/wco/public/global/pdf/topics/nomenclature/covid_19/prioritization-medicines-list-during-covid_19-_v9_wco_en.pdf?la=en.

[12] WEF (2019), “Outbreak Readiness and Business Impact: Protecting Lives and Livelihoods across the Global Economy”, World Economic Forum, Geneva, http://www3.weforum.org/docs/WEF%20HGHI_Outbreak_Readiness_Business_Impact.pdf.

[30] WHO (2020), Access to COVID-19 Tools (ACT) Accelerator, https://www.who.int/who-documents-detail/access-to-covid-19-tools-(act)-accelerator (accessed on 27 April 2020).

[26] WHO (2020), COVID-19 response, World Health Assembly Resolution.

[49] WHO (2020), Pandemic Supply Chain Network - Oxygen Therapy Survey - Medical Equipment COVID-19, https://extranet.who.int/dataformv3/index.php/754894?lang=en (accessed on 14 May 2020).

[52] Wolfe, R. (2020), “Exposing governments swimming naked in the COVID-19 crisis with trade policy transparency (and why WTO reform matters more than ever)”, in Baldwin, R. and S. Evenett (eds.), COVID-19 and Trade Policy: Why Turning Inward Won’t Work, Voxeu, https://www.globaltradealert.org/reports/53 (accessed on 14 May 2020).

[39] WTO (2020), Export Prohibitions and Restrictions, https://www.wto.org/english/tratop_e/covid19_e/export_prohibitions_report_e.pdf (accessed on 27 May 2020).

[35] WTO (2020), Standards, Regulations and Covid-19 - what actions taken by WTO Members?, https://docs.wto.org/ (accessed on 27 May 2020).

[16] WTO (2020), Transparency - Why it matters at times of crisis, https://www.wto.org/english/tratop_e/covid19_e/covid19_e.htm (accessed on 17 April 2020).

Annex 1.A. Covid-19 websites of selected international organisations


International Organisation


Covid-19 dedicated website

ASTM International



Bureau International des Poids et Mesures





Collaborative Arrangement for the Prevention and Management of Public Health Events in Civil Aviation (CAPSCA)


European Commission



Food and Agriculture Organization



International Atomic Energy Agency



International Air Transport Association



International Civil Aviation Organization



International Electronical Commission



International Federation of Accountants



International Labour Organization



International Monetary Fund



International Maritime Organisation





International Organization for Migration



International Organization for Standardization



International Telecommunication Union



Organisation for Economic Co-operation and Development



United Nations



UN Development Programme



UN Conference on Trade and Development



UN Environment Programme



UN Industrial Development Organization



World Tourism Organization



Universal Postal Union



World Customs Organization



World Health Organization



World Trade Organization




Marianna Karttunen: [email protected]

Céline Kauffmann: [email protected]

Camila Saffirio: [email protected]



On Removing administrative barriers, improving regulatory delivery; on The use of new technologies to expand regulatory capacity; on The use of regulatory management tools and the role of regulatory oversight; on Behavioural insights; and Sector regulation during the COVID-19 crisis, available at: www.oecd.org/gov/regulatory-policy/reg-covid-19-activities.htm.


In favour of a global approach to prevent countries from “reinfecting” each other, see also (Gates, 2020[94]).


Regulation is the diverse set of instruments by which governments set requirements on enterprises and citizens. Regulation include all laws, formal and informal orders, subordinate rules, administrative formalities and rules issued by non-governmental or self-regulatory bodies to whom governments have delegated regulatory powers (OECD, 2018[19]).


See the tripartite guidance developed by the FAO, OIE and WHO to ensure a multisectoral response to zoonotic diseases (FAO, 2019[97]).


The Bill & Melinda Gates Foundation (BMGF), CEPI, GAVI, Global Fund, UNITAID, Welcome Trust, and WHO.


For example, the US FDA has issued Emergency Use Authorizations (EUAs) for in vitro diagnostic products, specific laboratory developed tests, personal protective equipment, ventilators and other medical devices, and therapeutics (US Food and Drug Administrator, 2020[95]). Similarly, a number of countries have put in place emergency authorisations for disinfectant products (Diderich and Poret, 2020[65]) A full list with information on country measures implemented to manage the emergency supply and increase availability of disinfectant products has been collected by the OECD: http://www.oecd.org/chemicalsafety/pesticides-biocides/emergency-responses-for-the-supply-of-disinfectants-against-covid-19.htm#C.




Commission Implementing Regulation (EU) 2020/402 of 14 March 2020 making the exportation of certain products subject to the production of an export authorisation https://eur-lex.europa.eu/legal-content/en/txt/?uri=uriserv:oj.li.2020.077.01.0001.01.eng&toc=oj:l:2020:077i:toc.


Communication from the Commission Guidance note to Member States related to Commission Implementing Regulation (EU) 2020/402 making the exportation of certain products subject to the production of an export authorisation https://eur-lex.europa.eu/legal-content/en/txt/?qid=1587142591885&uri=celex:52020xc0320(04).


“We recognise the importance of transparency and commend the Trade and Investment Ministers' commitment to notify the WTO of any trade-related measures taken, including those related to agriculture and essential foodstuffs” (G20, 2020[47]) See also (G20, 2020[96]).


“Step-by-step video on how to set up an email alert on COVID-19 related notifications" -https://youtu.be/Ob5ou6rYYH0.


Joint initiative of the Commonwealth Small States Office, the Global Alliance for Trade Facilitation, the International Air Transport Association, the International Trade Centre, the United Nations Conference on Trade and Development, World Customs Organisation and the World Trade Organisation, https://www.tfafacility.org/covid19-trade-facilitation


See WTO Agreement on technical Barriers to Trade, Preamble, 8th recital www.wto.org/english/tratop_e/tbt_e/tbt_e.htm.


In the EU countries, the majority of standards stems from the EU standard-setting bodies and are incorporated into national regulations.


Harmonised in Regulation (EU) 2016/425.


Mutual recognition (MR) can fall on rules or conformity assessment procedures. MR of rules means that the regulatory objectives or effective results of regulation for goods coming from the first country are regarded as ‘equivalent’ in the second, implicitly or explicitly, and vice versa. MR of procedures and results of conformity assessment refers to the capability of conformity assessment bodies in one country to perform testing and certification on selected goods to be exported to a second country, against the rules, standards and conformity assessment methods in the latter, and vice versa.


Co-ordinated effort between International Civil Aviation Organization (ICAO), Airports Council International (ACI), Civil Air Navigation Services (CANSO), International Air Transport Association (IATA), International Air Cargo Association (TIACA), World Food Programme (WFP) and the World Health Organisation (WHO) www.icao.int/Security/COVID-19/Pages/default.aspx.


See for instance case of the Diamon Princess cruise where 691 cases of COVID-19 were found, with passengers of 56 different nationalities (Nakazawa, Ino and Akabayashi, 2020[76]), or French Aircraft Carrier Charles de Gaulle where more than 1 000 crew members were contaminated (Breeden, 2020[99]).


The Roadmap reads: “De-escalating from the COVID-19-imposed measures in a coordinated manner is a matter of common European interest. (…)The containment measures, and their gradual relaxation, affect not only public health but also highly integrated value chains, as well as national and cross-border transport systems necessary to enable the free movement of people, goods and services. The integrated nature of the Single Market should therefore be kept in mind when lifting these measures.”


See Removing administrative barriers, improving regulatory delivery and The use of new technologies to expand regulatory capacity at: www.oecd.org/gov/regulatory-policy/reg-covid-19-activities.htm.


Work is underway in the framework of the Network of Economic Regulators on Sector Regulation During and After the COVID-19 Crisis (www.oecd.org/gov/regulatory-policy/reg-covid-19-activities.htm).


An illustration of these perceptions is provided by the Washington Post Article on Global institutions are flailing in the face of the pandemic, 15 April 2020.


See for example the Joint statement by WTO Director-General Roberto Azevêdo and WHO Director-General Tedros Adhanom Ghebreyesus (www.who.int/news-room/detail/20-04-2020-joint-statement-by-wto-director-general-roberto-azev%C3%AAdo-and-who-director-general-tedros-adhanom-ghebreyesus), the Joint Statement by the Directors-General of FAO, WHO and WTO to avoid measures that unduly restrict trade and spark food shortages (www.wto.org/english/news_e/news20_e/igo_26mar20_e.htm), the joint ICAO/WHO statement recalling the existing international standards related to safety in civil aviation and the importance of cross sector collaboration (www.icao.int/Security/COVID-19/Pages/Statements.aspx).


Other explaining factors discussed in the literature include information capture and funding structure. In many IOs, traditional core funding is increasingly replaced by voluntary contributions, which allow the donors a certain margin to decide on issues covered. While a transversal theme to IOs, specific papers dealing with these aspects in relation to WHO include (Berman, 2020[98]) and (Burci and Daugirdas, 2019[100]).